

Title:

Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

Authors and affiliations:

Nicole M Warrington^{1,a}, Robin N Beaumont^{2,a}, Momoko Horikoshi^{3,4,5,a}, Felix R Day^{6,a}, Øyvind Helgeland^{7,8,9,a}, Charles Laurin^{10,11}, Jonas Bacelis¹², Shouneng Peng^{13,14}, Ke Hao^{13,14}, Bjarke Feenstra¹⁵, Andrew R Wood², Anubha Mahajan^{3,4}, Jessica Tyrrell^{2,16}, Neil R Robertson^{3,4}, N William Rayner^{3,4,17}, Zhen Qiao¹, Gunn-Helen Øiseth Moen^{18,19}, Marc Vaudel⁸, Carmen J Marsit²⁰, Jia Chen²¹, Michael Nodzenski²², Theresia M Schnurr²³, Mohammad H Zafarmand^{24,25}, Jonathan P Bradfield^{26,27}, Niels Grarup²³, Marjolein N Kooijman^{28,29,30}, Ruifang Li-Gao³¹, Frank Geller¹⁵, Tarunveer S Ahluwalia^{23,32,33}, Lavinia Paternoster¹⁰, Rico Rueedi^{34,35}, Ville Huikari³⁶, Jouke-Jan Hottenga^{37,38,39}, Leo-Pekka Lyytikäinen⁴⁰, Alana Cavadino^{41,42}, Sarah Metrustry⁴³, Diana L Cousminer^{44,45}, Ying Wu⁴⁶, Elisabeth Thiering^{47,48}, Carol A Wang⁴⁹, Christian T Have²³, Natalia Vilor-Tejedor^{50,51}, Peter K Joshi⁵², Jodie N Painter⁵³, Ioanna Ntalla⁵⁴, Ronny Myhre⁵⁵, Niina Pitkänen⁵⁶, Elisabeth M van Leeuwen²⁹, Raimo Joro⁵⁷, Vasiliki Lagou^{3,58,59}, Rebecca C Richmond^{10,11}, Ana Espinosa^{60,61,62,63}, Sheila J Barton⁶⁴, Hazel M Inskip^{64,65}, John W Holloway⁶⁶, Loreto Santa-Marina^{60,67,68}, Xavier Estivill^{69,70}, Wei Ang⁷¹, Julie A Marsh⁷¹, Christoph Reichetzeder^{72,73}, Letizia Marullo⁷⁴, Berthold Hoher^{72,75}, Kathryn L Lunetta^{76,77}, Joanne M Murabito^{77,78}, Caroline L Relton^{10,11,79}, Manolis Kogevinas^{60,61,62,63}, Leda Chatzi⁸⁰, Catherine Allard⁸¹, Luigi Bouchard^{81,82,83}, Marie-France Hivert^{84,85,86}, Ge Zhang^{87,88,89}, Louis J Muglia^{87,88,89}, Jani Heikkinen⁹⁰, Early Growth Genetics (EGG) Consortium^b, Camilla S Morgen⁹¹, Antoine HC van Kampen^{92,93}, Barbera DC van Schaik⁹², Frank D Mentch²⁶, Claudia Langenberg⁶, Jian'an Luan⁶, Robert A Scott⁶, Jing Hua Zhao⁶, Gibran Hemani^{10,11}, Susan M Ring^{10,11}, Amanda J Bennett⁴, Kyle J Gaulton^{3,94}, Juan Fernandez-Tajes³, Natalie R van Zuydam^{3,4}, Carolina Medina-Gomez^{28,29,95}, Hugoline G de Haan³¹, Frits R Rosendaal³¹, Zoltán Kutalik^{34,96}, Pedro Marques-Vidal⁹⁷, Shikta Das⁴², Gonneke Willemsen^{37,38,39}, Hamdi Mbarek^{37,38,39,98}, Martina Müller-Nurasyid^{99,100,101}, Marie Standl⁴⁷, Emil V R Appel²³, Cilius E Fonvig^{23,102,103}, Caecilie Trier^{23,102}, Catharina EM van Beijsterveldt³⁸, Mario Murcia^{60,104}, Mariona Bustamante^{60,61,62}, Sílvia Bonas-Guarch¹⁰⁵, David M Hougaard¹⁰⁶, Josep M Mercader^{105,107,108}, Allan Linneberg^{109,110}, Katharina E Schraut⁵², Penelope A Lind⁵³, Sarah E Medland⁵³, Beverley M Shields¹¹¹, Bridget A Knight¹¹¹, Jin-Fang Chai¹¹², Kalliope Panoutsopoulou¹⁷, Meike Bartels^{37,38,39}, Friman Sánchez^{105,113}, Jacob Stokholm³², David Torrents^{105,114}, Rebecca K Vinding³², Sara M Willems²⁹, Mustafa Atalay⁵⁷, Bo L Chawes³², Peter Kovacs¹¹⁵, Inga Prokopenko^{3,116}, Marcus A Tuke², Hanieh Yaghootkar¹¹⁷, Katherine S Ruth², Samuel E Jones², Po-Ru Loh^{118,119}, Anna Murray², Michael N Weedon², Anke Tönjes¹²⁰, Michael Stumvoll^{115,120}, Kim F Michaelsen¹²¹, Aino-Maija Eloranta⁵⁷, Timo A Lakka^{57,122,123}, Cornelia M van Duijn²⁹, Wieland Kiess¹²⁴, Antje Körner^{115,124}, Harri Niinikoski^{125,126}, Katja Pahlkala^{56,127}, Olli T Raitakari^{56,128}, Bo Jacobsson^{7,12}, Eleftheria Zeggini¹⁷, George V Dedoussis¹²⁹, Yik-Ying Teo^{112,130,131}, Seang-Mei Saw^{112,132}, Grant W Montgomery⁵³, Harry Campbell⁵², James F Wilson^{52,133}, Tanja GM Vrijkotte²⁴, Martine Vrijheid^{60,61,62}, Eco JCN de Geus^{37,38,39}, M Geoffrey Hayes¹³⁴, Haja N Kadarmideen¹³⁵, Jens-Christian Holm^{23,102}, Lawrence J Beilin¹³⁶, Craig E Pennell⁴⁹, Joachim Heinrich^{47,137}, Linda S Adair¹³⁸, Judith B Borja^{139,140}, Karen L Mohlke⁴⁶, Johan G Eriksson^{141,142,143}, Elisabeth E Widén⁹⁰, Andrew T Hattersley^{2,111}, Tim D Spector⁴³, Mika Kähönen¹⁴⁴, Jorma S Viikari^{145,146},

48 Terho Lehtimäki⁴⁰, Dorret I Boomsma^{37,38,39,98}, Sylvain Sebert^{36,147,148,149}, Peter
 49 Vollenweider⁹⁷, Thorkild IA Sørensen^{10,23,91}, Hans Bisgaard³², Klaus Bønnelykke³², Jeffrey C
 50 Murray¹⁵⁰, Mads Melbye^{15,151}, Ellen A Nohr¹⁵², Dennis O Mook-Kanamori^{31,153}, Fernando
 51 Rivadeneira^{28,29,95}, Albert Hofman²⁹, Janine F Felix^{28,29,30}, Vincent WV Jaddoe^{28,29,30}, Torben
 52 Hansen²³, Charlotta Pisinger¹⁵⁴, Allan A Vaag^{109,155}, Oluf Pedersen²³, André G
 53 Uitterlinden^{28,29,95}, Marjo-Riitta Järvelin^{36,147,148,156,157}, Christine Power⁴², Elina
 54 Hyppönen^{42,158,159}, Denise M Scholtens²², William L Lowe Jr¹³⁴, George Davey Smith^{10,11,160},
 55 Nicholas J Timpson^{10,11}, Andrew P Morris^{3,161,162}, Nicholas J Wareham⁶, Hakon
 56 Hakonarson^{26,44,163}, Struan FA Grant^{26,44,45,163}, Timothy M Frayling², Debbie A Lawlor^{10,11,160},
 57 Pål R Njølstad^{8,9}, Stefan Johansson^{8,164}, Ken K Ong^{6,165,c}, Mark I McCarthy^{3,4,166,c}, John RB
 58 Perry^{6,c}, David M Evans^{1,10,11,c,d}, Rachel M Freathy^{2,10,c,d}

- 59
- 60 1. University of Queensland Diamantina Institute, Translational Research Institute,
- 61 Brisbane, Australia
- 62 2. Institute of Biomedical and Clinical Science, University of Exeter Medical School,
- 63 University of Exeter, Royal Devon and Exeter Hospital, Exeter, UK
- 64 3. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
- 65 4. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford,
- 66 Oxford, UK
- 67 5. RIKEN, Centre for Integrative Medical Sciences, Laboratory for Endocrinology,
- 68 Metabolism and Kidney diseases, Yokohama, Japan
- 69 6. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
- 70 Cambridge, UK
- 71 7. Department of Genetics and Bioinformatics, Domain of Health Data and Digitalisation,
- 72 Norwegian Institute of Public Health, Oslo, Norway
- 73 8. KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of
- 74 Bergen, Bergen, Norway
- 75 9. Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
- 76 10. Medical Research Council Integrative Epidemiology Unit at the University of Bristol,
- 77 Bristol, UK
- 78 11. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- 79 12. Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of
- 80 Gothenburg, Gothenburg, Sweden
- 81 13. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
- 82 Sinai, New York, USA
- 83 14. Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount
- 84 Sinai, New York, USA
- 85 15. Department of Epidemiology Research, Statens Serum Institute, Copenhagen,
- 86 Denmark
- 87 16. European Centre for Environment and Human Health, University of Exeter, Truro, UK
- 88 17. Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK
- 89 18. Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo
- 90 University Hospital, Oslo, Norway
- 91 19. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- 92 20. Environmental Health at Rollins School of Public Health, Emory University, Atlanta, USA
- 93 21. Department of Environmental Medicine and Public Health, Icahn School of Medicine at
- 94 Mount Sinai, New York, USA

- 95 22. Department of Preventive Medicine, Division of Biostatistics, Feinberg School of
96 Medicine, Northwestern University, Chicago, USA
- 97 23. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic
98 Genetics, Faculty of Health and Medical Sciences, University of Copenhagen,
99 Copenhagen, Denmark
- 100 24. Department of Public Health, Amsterdam Public Health Research Institute, Academic
101 Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands
- 102 25. Department of Clinical Epidemiology and Biostatistics, Amsterdam Public Health
103 Research Institute, Academic Medical Center (AMC), University of Amsterdam, the
104 Netherlands
- 105 26. Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, USA
- 106 27. Quantinuum Research LLC, San Diego, USA
- 107 28. The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam,
108 Rotterdam, the Netherlands
- 109 29. Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam,
110 Rotterdam, the Netherlands
- 111 30. Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam,
112 Rotterdam, the Netherlands
- 113 31. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the
114 Netherlands
- 115 32. COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and
116 Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
- 117 33. Steno Diabetes Center, Gentofte, Denmark
- 118 34. Swiss Institute of Bioinformatics, Lausanne, Switzerland
- 119 35. Department of Computational Biology, University of Lausanne, Lausanne, Switzerland
- 120 36. Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu,
121 Finland
- 122 37. Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, the
123 Netherlands
- 124 38. Netherlands Twin Register, Department of Biological Psychology, VU University,
125 Amsterdam, the Netherlands
- 126 39. Amsterdam Public Health, Amsterdam, the Netherlands
- 127 40. Department of Clinical Chemistry, Fimlab Laboratories, and Finnish Cardiovascular
128 Research Center - Tampere, Faculty of Medicine and Life Sciences, University of
129 Tampere, Tampere, Finland
- 130 41. Section of Epidemiology & Biostatistics, School of Population Health, University of
131 Auckland, Auckland, New Zealand
- 132 42. Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health,
133 University College London, London, UK
- 134 43. Department of Twin Research, King's College London, St. Thomas' Hospital, London, UK
- 135 44. Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, USA
- 136 45. Department of Genetics, Perelman School of Medicine, University of Pennsylvania,
137 Philadelphia, USA
- 138 46. Department of Genetics, University of North Carolina, Chapel Hill, USA
- 139 47. Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for
140 Environmental Health, Neuherberg, Germany

- 141 48. Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital,
142 University of Munich Medical Center, Munich, Germany
- 143 49. School of Medicine and Public Health, Faculty of Medicine and Health, The University
144 of Newcastle, Callaghan, Australia
- 145 50. Center for Genomic Regulation (CRG), the Barcelona Institute of Science and
146 Technology, Barcelona, Spain
- 147 51. Barcelonabeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona,
148 Spain
- 149 52. Usher Institute for Population Health Sciences and Informatics, University of
150 Edinburgh, Edinburgh, UK
- 151 53. QIMR Berghofer Medical Research Institute, Locked Bag 2000, Royal Brisbane Hospital,
152 Herston, Australia
- 153 54. William Harvey Research Institute, Barts and the London School of Medicine and
154 Dentistry, Queen Mary University of London, London, UK
- 155 55. Department of Genes and Environment, Division of Epidemiology, Norwegian Institute
156 of Public Health, Oslo, Norway
- 157 56. Research Centre of Applied and Preventive Cardiovascular Medicine, University of
158 Turku, Turku, Finland
- 159 57. Institute of Biomedicine, Physiology, University of Eastern Finland, Kuopio, Finland
- 160 58. KU Leuven - University of Leuven, Department of Neuroscience, Leuven, Belgium
- 161 59. VIB Center for Brain and Disease Research, Leuven, Belgium
- 162 60. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- 163 61. ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain
- 164 62. Universitat Pompeu Fabra (UPF), Barcelona, Spain
- 165 63. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- 166 64. Medical Research Council Lifecourse Epidemiology Unit, University of Southampton,
167 Southampton, UK
- 168 65. NIHR Southampton Biomedical Research Centre, University of Southampton and
169 University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 170 66. Human Development & Health, Faculty of Medicine, University of Southampton,
171 Southampton, UK
- 172 67. Subdirección de Salud Pública y Adicciones de Gipuzkoa, Donostia/San Sebastián, Spain
- 173 68. Instituto de Investigación Sanitaria BIODONOSTIA, Donostia/San Sebastián, Spain
- 174 69. Sidra Medicine Research, Sidra Medicine, Doha, Qatar
- 175 70. Genomics Unit, Dexeus Woman's Health, Barcelona, Spain
- 176 71. Division of Obstetrics and Gynaecology, The University of Western Australia, Crawley,
177 Australia
- 178 72. Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany
- 179 73. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin,
180 Germany
- 181 74. Department of Life Sciences and Biotechnology, Genetic Section, University of Ferrara,
182 Ferrara, Italy
- 183 75. The First Affiliated Hospital of Jinan University, Guangzhou, China
- 184 76. Boston University School of Public Health, Department of Biostatistics, Boston,
185 Massachusetts, USA
- 186 77. Framingham Heart Study, Framingham, USA

- 187 78. Boston University School of Medicine Department of Medicine, Section of General
188 Internal Medicine, Boston, USA
- 189 79. Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
- 190 80. Department of Preventive Medicine, Keck School of Medicine, University of Southern
191 California, Los Angeles, USA
- 192 81. Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke,
193 Canada
- 194 82. ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, Saguenay, Canada
- 195 83. Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Canada
- 196 84. Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard
197 Medical School, Boston, USA
- 198 85. Diabetes Center, Massachusetts General Hospital, Boston, USA
- 199 86. Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada
- 200 87. Center for Prevention of Preterm Birth, Perinatal Institute, Cincinnati Children's
201 Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of
202 Medicine, Cincinnati, USA
- 203 88. March of Dimes Prematurity Research Center Ohio Collaborative, Cincinnati, USA
- 204 89. Human Genetics Division, Cincinnati Children's Hospital Medical Center, Cincinnati,
205 USA
- 206 90. Institute for Molecular Medicine, Finland (FIMM), University of Helsinki, Helsinki,
207 Finland
- 208 91. Department of Public Health, Section of Epidemiology, Faculty of Health and Medical
209 Sciences, University of Copenhagen, Copenhagen, Denmark
- 210 92. Bioinformatics Laboratory, Clinical Epidemiology, Biostatistics and Bioinformatics
211 (KEBB), Amsterdam Public Health Research Institute, Academic Medical Center /
212 University of Amsterdam, Amsterdam, the Netherlands
- 213 93. Biosystems Data Analysis, Swammerdam Institute for Life Sciences (SILS), University of
214 Amsterdam, Amsterdam, the Netherlands
- 215 94. Department of Pediatrics, University of California San Diego, La Jolla, California, USA
- 216 95. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam,
217 Rotterdam, the Netherlands
- 218 96. Institute of Social and Preventive Medicine, Lausanne University Hospital (CHUV),
219 Lausanne, Switzerland
- 220 97. Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV),
221 Lausanne, Switzerland
- 222 98. Amsterdam Reproduction and Development, Amsterdam, the Netherlands
- 223 99. Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research
224 Center for Environmental Health, Neuherberg, Germany
- 225 100. Department of Medicine I, Ludwig-Maximilians-Universität, Munich, Germany
- 226 101. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart
227 Alliance, Munich, Germany
- 228 102. The Children's Obesity Clinic, Department of Pediatrics, Copenhagen University
229 Hospital Holbæk, Holbæk, Denmark
- 230 103. Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense,
231 Denmark
- 232 104. FISABIO—Universitat Jaume I—Universitat de València, Joint Research Unit of
233 Epidemiology and Environmental Health, Valencia, Spain

- 234 105. Barcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in
235 Computational Biology, Barcelona Supercomputing Center, Barcelona, Spain
- 236 106. Danish Center for Neonatal Screening, Department for Congenital Disorders, Statens
237 Serum Institut, Copenhagen, Denmark
- 238 107. Programs in Metabolism and Medical & Population Genetics, Broad Institute of
239 Harvard and MIT, Cambridge, USA
- 240 108. Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital,
241 Boston,, USA
- 242 109. Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen
243 University, Copenhagen, Denmark
- 244 110. Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital,
245 The Capital Region, Frederiksberg, Denmark
- 246 111. NIHR Exeter Clinical Research Facility, University of Exeter Medical School and Royal
247 Devon and Exeter NHS Foundation Trust, Exeter, UK
- 248 112. Saw Swee Hock School of Public Health, National University of Singapore, National
249 University Health System, Singapore, Singapore
- 250 113. Computer Sciences Department, Barcelona Supercomputing Center, Barcelona, Spain
- 251 114. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
- 252 115. IFB Adiposity Diseases, University of Leipzig, Leipzig, Germany
- 253 116. Section of Genomics of Common Disease, Department of Medicine, Imperial College
254 London, London, UK
- 255 117. Genetics of Complex Traits, University of Exeter Medical School, Royal Devon and
256 Exeter Hospital, Exeter, UK
- 257 118. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT,
258 Cambridge, USA
- 259 119. Division of Genetics, Department of Medicine, Brigham and Women's Hospital and
260 Harvard Medical School, Boston, USA
- 261 120. Medical Department, University of Leipzig, Leipzig, Germany
- 262 121. Department of Nutrition, Exercise and Sports, Faculty of Science, University of
263 Copenhagen, Copenhagen, Denmark
- 264 122. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital,
265 Kuopio, Finland
- 266 123. Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
- 267 124. Pediatric Research Center, Department of Women's & Child Health, University of
268 Leipzig, Leipzig, Germany
- 269 125. Department of Pediatrics, Turku University Hospital, Turku, Finland
- 270 126. Department of Physiology, University of Turku, Turku, Finland
- 271 127. Paavo Nurmi Centre, Sports and Exercise Medicine Unit, Department of Physical
272 Activity and Health, Turku, Finland
- 273 128. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital,
274 Turku, Finland
- 275 129. Department of Nutrition and Dietetics, School of Health Science and Education,
276 Harokopio University, Athens, Greece
- 277 130. Department of Statistics and Applied Probability, National University of Singapore,
278 Singapore, Singapore
- 279 131. Life Sciences Institute, National University of Singapore, Singapore, Singapore
- 280 132. Singapore Eye Research Institute, Singapore, Singapore

- 281 133. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of
282 Edinburgh, Edinburgh, UK
- 283 134. Department of Medicine, Division of Endocrinology, Metabolism, and Molecular
284 Medicine, Feinberg School of Medicine, Northwestern University, Chicago, USA
- 285 135. Quantitative and Systems Genomics Group, Department of Bio and Health Informatics,
286 Technical University of Denmark, Kgs. Lyngby, Denmark
- 287 136. School of Medicine and Pharmacology, Royal Perth Hospital Unit, The University of
288 Western Australia, Perth, Australia
- 289 137. Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine,
290 Inner City Clinic, University Hospital Munich, Ludwig Maximilian University of Munich,
291 Munich, Germany
- 292 138. Department of Nutrition, University of North Carolina, Chapel Hill, USA
- 293 139. USC-Office of Population Studies Foundation, Inc., University of San Carlos, Cebu City,
294 Philippines
- 295 140. Department of Nutrition and Dietetics, University of San Carlos, Cebu City, Philippines
- 296 141. National Institute for Health and Welfare, Helsinki, Finland
- 297 142. Department of General Practice and Primary Health Care, University of Helsinki and
298 Helsinki University Hospital, Helsinki, Finland
- 299 143. Folkhälsan Research Center, Helsinki, Finland
- 300 144. Department of Clinical Physiology, Tampere University Hospital, and Finnish
301 Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences,
302 University of Tampere, Tampere, Finland
- 303 145. Division of Medicine, Turku University Hospital, Turku, Finland
- 304 146. Department of Medicine, University of Turku, Turku, Finland
- 305 147. Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and
306 Health, School of Public Health, Imperial College London, London, UK
- 307 148. Biocenter Oulu, University of Oulu, Oulu, Finland
- 308 149. Department of Genomics of Complex Diseases, Imperial College London, London, UK
- 309 150. Department of Pediatrics, University of Iowa, Iowa City, USA
- 310 151. Department of Medicine, Stanford School of Medicine, Stanford, USA
- 311 152. Research Unit for Gynaecology and Obstetrics, Institute of Clinical Research, University
312 of Southern Denmark, Odense, Denmark
- 313 153. Department of Public Health and Primary Care, Leiden University Medical Center,
314 Leiden, the Netherlands
- 315 154. Research Center for Prevention and Health Capital Region, Center for Sundhed,
316 Rigshospitalet – Glostrup, Copenhagen University, Glostrup, Denmark
- 317 155. Cardiovascular and Metabolic Disease Translational Medicine Unit, Early Clinical
318 Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
- 319 156. Unit of Primary Health Care, Oulu University Hospital, Oulu, Finland
- 320 157. Department of Life Sciences, College of Health and Life Sciences, Brunel University
321 London, Middlesex, UK
- 322 158. Australian Centre for Precision Health, University of South Australia Cancer Research
323 Institute, Adelaide, Australia
- 324 159. South Australian Health and Medical Research Institute, Adelaide, Australia
- 325 160. Bristol NIHR Biomedical Research Centre, Bristol, UK
- 326 161. Department of Biostatistics, University of Liverpool, Liverpool, UK
- 327 162. Estonian Genome Center, University of Tartu, Tartu, Estonia

- 328 163. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania,
 329 Philadelphia, USA
 330 164. Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
 331 165. Department of Paediatrics, University of Cambridge, Cambridge, UK
 332 166. Oxford National Institute for Health Research (NIHR) Biomedical Research Centre,
 333 Churchill Hospital, Oxford, UK
 334

335 ^a These authors contributed equally to this work.

336 ^b A full list of the members is provided in the Supplementary Material.

337 ^c These authors jointly directed this work.

338 ^d Corresponding authors.
 339

Abstract:

Birth weight (BW) variation is influenced by fetal and maternal genetic and non-genetic factors, and has been reproducibly associated with future cardio-metabolic health outcomes. These associations have been proposed to reflect the lifelong consequences of an adverse intrauterine environment. In earlier work, we demonstrated that much of the negative correlation between BW and adult cardio-metabolic traits could instead be attributable to shared genetic effects. However, that work and other previous studies did not systematically distinguish the direct effects of an individual's own genotype on BW and subsequent disease risk from indirect effects of their mother's correlated genotype, mediated by the intrauterine environment. Here, we describe expanded genome-wide association analyses of own BW (n=321,223) and offspring BW (n=230,069 mothers), which identified 278 independent association signals influencing BW (214 novel). We used structural equation modelling to decompose the contributions of direct fetal and indirect maternal genetic influences on BW, implicating fetal- and maternal-specific mechanisms. We used Mendelian randomization to explore the causal relationships between factors influencing BW through fetal or maternal routes, for example, glycemic traits and blood pressure. Direct fetal genotype effects dominate the shared genetic contribution to the association between lower BW and higher type 2 diabetes risk, whereas the relationship between lower BW and higher later blood pressure (BP) is driven by a combination of indirect maternal and direct fetal genetic effects: indirect effects of maternal BP-raising genotypes act to reduce offspring BW, but only direct fetal genotype effects (once inherited) increase the offspring's later BP. Instrumental variable analysis using maternal BW-lowering genotypes to proxy for an adverse intrauterine environment provided no evidence that it causally raises offspring BP. In successfully separating fetal from maternal genetic effects, this work represents an important advance in genetic studies of perinatal outcomes, and shows that the association between lower BW and higher adult BP is attributable to genetic effects, and not to intrauterine programming.

Birth weight (BW) is an important predictor of newborn and infant survival, a key indicator of pregnancy outcomes for mothers as well as for offspring, and is observationally associated with future risk of adult cardio-metabolic diseases in the offspring.

Observational associations between lower BW and later cardio-metabolic diseases are often assumed to reflect adaptations made by a developing fetus in response to an adverse intrauterine environment, such as maternal malnutrition. This concept has been termed the Developmental Origins of Health and Disease (DOHaD) hypothesis¹. Support of the DOHaD hypothesis is primarily from animal models (reviewed in ²). Observational studies of famine-exposed populations support prenatal programming in relation to body size and diabetes, but not other cardio-metabolic health measures (reviewed in ³). However, DOHaD cannot provide a complete explanation for the relationship between lower BW and increased risk of cardio-metabolic disease. Other likely contributing factors are (i) environmental confounding, leading to phenotypic associations across the life-course⁴, and (ii) shared genetic effects operating at the population level, as demonstrated in our recent work showing overlap between genetic variants influencing BW and adult cardio-metabolic diseases⁵. Genetic associations between BW and later cardio-metabolic diseases may arise from the direct effects of the same inherited genetic variants at different stages of the life-course⁶. However, consideration of an individual's own genotype in isolation cannot exclude potential confounding by any indirect effects of the correlated maternal genotype ($r \approx 0.5$) on the intrauterine, and possibly postnatal, environment. Evidence for maternal indirect effects on BW and later offspring disease risk could indicate the role of the intrauterine environment in later-life disease etiology.

To date, 65 genomic loci have been associated with BW in genome-wide association studies (GWAS), implicating biological pathways that may underlie observational associations with adult disease^{5,7-9}. However, most of these studies did not distinguish between maternal and fetal genetic influences on BW. Evidence from monogenic human models¹⁰ and variance components analyses¹¹ demonstrate that BW is influenced both by genotypes inherited by the fetus and by maternal genotypes that influence the intrauterine environment. To date, GWAS of own BW⁵ and offspring BW⁷, which have focused on the fetal and maternal genome respectively, have produced overlapping signals due to the correlation between maternal and fetal genotypes. Identified BW variants might have (i) a direct fetal effect only, (ii) an indirect maternal effect only, or (iii) some combination of the two. Performing separate GWAS analyses of own or offspring BW precludes full resolution of the origin of the identified genetic effects. For example, some association signals identified in a GWAS of own BW may in fact be the exclusive consequence of strong indirect maternal effects (and vice versa).

To address these issues, we performed greatly-expanded GWAS of own BW ($n=321,223$) and offspring BW ($n=230,069$ mothers) using data from the EGG Consortium and the UK Biobank (2017 release). We applied a statistical method that we recently developed, which utilises structural equation modelling (SEM), to partition genetic effects on BW into maternal and fetal components at genome-wide significant loci^{7,12}. We then extended the method to estimate maternal- and fetal-specific genetic effects across the genome in a computationally efficient manner, and used the results for downstream analyses. Our ability to resolve maternal and fetal genetic contributions provides substantial insights into the underlying

415 biological regulation of BW and into the origins of observational relationships with type 2
416 diabetes (T2D) and blood pressure (BP).

RESULTS

Meta-analyses of fetal and maternal GWAS

We conducted GWAS meta-analyses of own (fetal) genetic variants on own BW (**Supplementary Figure 1, Supplementary Tables 1 and 2**) and maternal genetic variants on offspring BW (**Supplementary Figure 2, Supplementary Tables 3 and 4**) in individuals of European ancestry. We then performed approximate conditional and joint multiple-SNP analysis (COJO¹³) and a trans-ethnic meta-analysis to identify further independent SNPs (**Methods**). The GWAS meta-analysis of own BW (N=321,223) identified 211 independent single nucleotide polymorphisms (SNPs) at genome-wide significance ($P < 5 \times 10^{-8}$) (**Supplementary Figures 3, 4, 5a, Supplementary Table 5, and Methods**). The GWAS meta-analysis of offspring BW (N=230,069 mothers) identified 105 independently associated SNPs ($P < 5 \times 10^{-8}$; **Supplementary Figures 3, 4, 5b, Supplementary Table 5, and Methods**). When we applied a more stringent significance threshold that accounts for the large number of low frequency SNPs imputed in the UK Biobank and EGG studies ($P < 6.6 \times 10^{-9}$; see Kemp et al.¹⁴ for details of the derivation of this threshold), 147 of the 211 SNPs from the GWAS meta-analysis of own BW and 72 of the 105 SNPs from the GWAS meta-analysis of offspring BW remained significant (**Supplementary Table 5**).

SNPs at 52 genome-wide significant loci (within 500Kb) were identified in the GWAS of both own BW and offspring BW. Of these, 11 loci had the same lead SNP and a further 31 loci had fetal and maternal lead SNPs correlated with $r^2 \geq 0.1$. Colocalization analysis indicated 27/31 of these maternal and fetal lead SNP pairs were likely tagging the same BW signal (posterior probability > 0.5). Therefore, we identified a total of 278 independent association signals, represented by 305 SNPs (**Supplementary Figure 4 and Supplementary Table 5**). Of the 305 genome-wide significant SNPs, 238 were novel representing 214 independent association signals, four of the identified SNPs are rare (minor allele frequency (MAF) < 1%) and 21 are low-frequency ($1\% \leq \text{MAF} < 5\%$). Three of the rare variants (*YKT6/GCK*, *ACVR1C* and *MIR146B*) alter BW by more than double the effect (>100g per allele) of the first common variants identified⁹. In the independent Norwegian MoBa-HARVEST study (N=13,934 mother-offspring duos), the variance in BW explained by fetal genetic variation was larger than that explained either by maternal genetic variation or the covariance between the two. The fetal genotype at the genome-wide significant SNPs explained 7% of the variance in BW, whereas the maternal genotype explained 3% and the covariance explained -0.5% (in total, the genome-wide significant SNPs explained 9% of the variance in BW, calculated as the sum of variances explained by the fetal genotype, maternal genotype, plus twice the covariance). Maternal genome-wide complex trait analysis (M-GCTA¹¹), which estimates SNP heritability and partitions this quantity into maternal and fetal components, estimated that a total of 39.8% of the variance in BW could be explained by tagged fetal genetic variation (28.5%), tagged maternal genetic variation (7.6%) and twice the covariance between the two (3.7%).

We integrated data from several sources to highlight possible causal genes underlying the identified associations, including gene-level expression data across 43 tissues (from GTEx v6p¹⁵), placental expression quantitative trait loci (eQTL¹⁶), topologically associating domains (TADs) identified in human embryonic stem cells^{17,18} and non-synonymous SNPs (see **Supplementary Table 5 and Methods**). Several genes were highlighted by multiple approaches; however, further functional studies are required to confirm causality.

Structural equation model to estimate maternal and fetal effects

We next partitioned the 305 genome-wide significant SNPs into five categories based on their maternal and/or fetal genetic contributions to BW. To achieve this, we used structural equation modelling (SEM) that accounts for the correlation between fetal and maternal genotypes and therefore potential confounding of the maternal and fetal effects on each other¹². Briefly, the model uses the self-reported BW data from the individuals in the UK Biobank, along with the BW data of the first offspring of the UK Biobank women. We model both grand-maternal and offspring genotypes (which were absent in the UK Biobank) as latent factors, in addition to the genotype data of the UK Biobank individual (**Supplementary Figure 17**). The model is robust to missing data and measurement error, so we could include individuals from the UK Biobank who have reported either their own (including women and men) or their offspring's BW (women only), but not both. Likewise, we can also include summary statistics from the EGG consortium to improve the estimation of the maternal and fetal effects (see **Methods** for full details). The model provides unbiased estimates of the maternal and fetal genetic effects on BW. We analysed 257,734 individuals of European descent from the UK Biobank (85,518 women with their own and their offspring's BW, 98,235 men or women with their own BW, and 73,981 women with only their offspring's BW) and incorporated the summary statistics from the EGG Consortium European meta-analysis of own BW (N=80,745) and offspring BW (N=19,861; **Figure 1, Supplementary Figures 4, 6 and Supplementary Table 5**). Using the confidence intervals around the SEM-adjusted maternal and fetal effect estimates, we identified 83 SNPs with fetal-only effects, 45 SNPs with maternal-only effects, 36 SNPs with directionally-concordant fetal and maternal effects, and 24 SNPs with directionally-opposing fetal and maternal effects (**Supplementary Figure 7**). For example, rs10830963 at *MTNR1B* was identified in both the own BW ($P=2.8 \times 10^{-11}$) and offspring BW ($P=9.1 \times 10^{-39}$) GWAS, but the SEM analysis revealed that its effect on BW was exclusively maternal ($P_{SEMfetal}=0.7$, $P_{SEMmaternal}=4.6 \times 10^{-19}$). Conversely, rs28457693 at *PTCH1/FANCC* (own BW GWAS: $P=9.9 \times 10^{-26}$; offspring BW GWAS: $P=3.7 \times 10^{-9}$) showed evidence of a fetal effect only ($P_{SEMfetal}=1.7 \times 10^{-9}$, $P_{SEMmaternal}=0.2$). SNP rs560887 at *G6PC2* was identified only in the GWAS of offspring BW ($P=1.2 \times 10^{-14}$), but was found to have directionally-opposing maternal and fetal effects on BW ($P_{SEMfetal}=2.8 \times 10^{-8}$, $P_{SEMmaternal}=5.4 \times 10^{-14}$). At present, these categories are suggestive as the current sample size has insufficient statistical power to detect small genetic effects, particularly maternal effects. There were 117 SNPs that were unclassified, and some of the SNPs that were classified as fetal only, for example, may have had a small maternal effect that was undetected with the current sample size. Asymptotic power calculations showed that with the current sample size we had 80% power to detect fetal (maternal) effects that explained 0.006% (0.008%) of the variance in BW ($\alpha=0.05$). However, there was strong consistency with traditional conditional linear regression modelling in N=18,873 mother-offspring pairs (**Supplementary Table 6 and Methods**), and overall, the method gave a clear indication as to which genetic associations are driven by the maternal or fetal genomes, respectively.

To extend the estimates of adjusted maternal and fetal effects genome-wide, we developed a weighted linear model (WLM) that yields a good approximation to the SEM (see **Methods**), with equivalent estimates for the 305 genome-wide significant SNPs (**Supplementary Figure 8**). This was necessary because the SEM is too computationally intensive to fit to a large number of SNPs across the genome. The resulting adjusted fetal

and maternal genotype effect estimates on BW from the WLM are hereafter referred to as WLM-adjusted estimates. Using linkage disequilibrium (LD) score regression¹⁹, we observed that the genetic correlation between the WLM-adjusted maternal and fetal effects ($r_g=0.10$, $P=0.12$) was substantially lower than that between the unadjusted effects from the original GWAS ($r_g=0.82$, $P<0.01$), indicating that the WLM largely accounts for the underlying correlation between fetal and maternal genotypes. No additional novel loci were identified in the WLM-adjusted analyses. We used these WLM-adjusted estimates in downstream analyses to identify fetal-specific and maternal-specific mechanisms that regulate BW and to investigate the genetic links between BW and adult traits.

Maternal- and fetal-specific tissues and mechanisms underlying BW regulation

Using the WLM-adjusted estimates, we observed differences in enrichment between the maternal and fetal profiles of gene expression across tissues, and of regulatory pathways. Tests of global enrichment of BW SNP associations across tissues sampled from the GTEx project¹⁵ using LD-SEG²⁰, indicated that the only tissues reaching significance after Bonferroni correction was enrichment for maternal-specific SNP associations for genes expressed in connective/bone tissues (**Supplementary Figure 9**). Integration of epigenetic signatures defined by the Roadmap Epigenomics project highlighted, after Bonferroni correction, a significant enrichment of maternal-specific effects in the ovary for histone modification marks (H3K4me1) and regions of open chromatin (**Supplementary Table 7**); no significant enrichment was detected for other signatures. Gene-set enrichment analysis using WLM-adjusted effect estimates also implicated different gene sets having fetal-specific influences on BW (**Supplementary Table 8**) to those having maternal-specific influences (**Supplementary Table 9**).

A major determinant of BW is the duration of gestation. We performed LD score regression analysis¹⁹ to investigate the genetic correlation between published maternal genotype effects on gestational duration²¹ and the WLM-adjusted BW effects. (To date, there is no published GWAS of fetal genotype and gestational duration.) We found a substantial genetic correlation with the WLM-adjusted maternal effects on offspring BW ($r_g=0.63$; $P=2.1 \times 10^{-5}$; **Supplementary Table 10**; see **Methods**), but not with the WLM-adjusted fetal effects on own BW ($r_g=-0.10$, $P=0.35$). Gestational duration was unavailable for >85% of individuals in the GWAS analyses, due to the large UK Biobank sample without gestational duration, so it is possible that some identified association signals influence BW primarily by altering the timing of delivery. We looked up the 305 genome-wide significant BW-associated SNPs in the published maternal GWAS of gestational duration²¹ (**Supplementary Table 11**) and followed up 6 SNPs in 13,206 mother-child pairs ($P<1.6 \times 10^{-4}$ with gestational duration, corrected for 305 tests, **Methods**). Meta-analyzing the results from the mother-child pairs with summary data from 23andMe²¹ strengthened associations with gestational duration at four of the six loci (*EBF1*, *AGTR2*, *ZBTB38* and *KCNAB1*; **Supplementary Table 12**). The precise causal relationship between fetal growth and gestational duration at these loci requires further investigation, however, the majority of associations with BW do not appear to be driven by associations with gestational duration.

Maternal- and fetal-specific genetic correlations between BW and adult traits

The 305 genome-wide significant BW-associated SNPs were collectively associated with a wide variety of other phenotypes in previously-published GWAS and in the UK Biobank (**Supplementary Table 13**; see **Methods**). At the genome-wide level, we previously reported genetic correlations between own BW and several adult cardio-metabolic disease traits⁵, for example systolic blood pressure (SBP; $r_g = -0.22$, $P = 5.5 \times 10^{-13}$), but at that time were unable to distinguish the direct fetal genotype contribution from the indirect contribution of maternal genotype. To understand these distinct contributions, we calculated genetic correlations using LD score regression¹⁹ between WLM-adjusted fetal and maternal SNP effect estimates and GWAS estimates for a large range of health-related traits (**Figure 2, Supplementary Table 10** and **Methods**). For many traits, for example adult height, the WLM-adjusted fetal effect on own BW ($r_g = 0.28$, $P = 8.1 \times 10^{-16}$) showed a similar genetic correlation to the WLM-adjusted maternal effect on offspring BW ($r_g = 0.29$, $P = 5.1 \times 10^{-16}$). However, for others, we observed differing fetal-specific and maternal-specific genetic correlations. For example, for several glycaemic traits (T2D, 2-hour glucose, fasting glucose, fasting insulin), there were directionally-opposite fetal (own BW) and maternal (offspring BW) genetic correlations. Moreover, the genetic correlations with glycaemic traits that were estimated using the WLM-adjusted effects were substantially larger than those estimated using the unadjusted effects, demonstrating the importance of accounting for the maternal-fetal genotype correlation (e.g. fasting glucose: WLM-adjusted fetal effect on own BW $r_g = -0.25$, $P = 8.2 \times 10^{-6}$; unadjusted fetal effect on own BW $r_g = -0.11$, $P = 0.005$; WLM-adjusted maternal effect on offspring BW $r_g = 0.20$, $P = 0.003$; unadjusted maternal effect on offspring BW $r_g = 0.08$, $P = 0.09$). Cardiovascular traits showed directionally consistent WLM-adjusted maternal and WLM-adjusted fetal genetic correlations, but with different strengths. For example, the genetic correlation between SBP and WLM-adjusted maternal effects on offspring BW ($r_g = -0.23$, $P = 9.2 \times 10^{-10}$) was stronger than that between SBP and WLM-adjusted fetal effects on own BW ($r_g = -0.14$, $P = 9.8 \times 10^{-5}$).

Using genetics to estimate causal effects of intrauterine exposures on birth weight

The separation of direct fetal genotype effects from indirect maternal genotype effects on BW offers the novel opportunity to estimate the unconfounded causal influences of intrauterine exposures using Mendelian randomization (MR) analyses. The principle of MR is similar to that of a randomized controlled trial: parental alleles are randomly transmitted to offspring and are therefore generally free from confounding^{22,23}. Consequently, an association between a maternal genetic variant for an exposure of interest, and offspring BW, after accounting for fetal genotype, provides evidence that the maternal exposure is causally related to offspring BW (**Figure 3A**). Previous attempts to estimate causal effects of maternal exposures on offspring BW were limited by an inability to adjust for fetal genotype in adequately-powered samples²⁴. However, this limitation can now be overcome by using WLM-adjusted estimates in a two-sample setting. We applied two-sample MR²⁵ to estimate causal effects of maternal exposures on offspring BW, focusing on height, glycaemic traits and SBP. We selected SNPs known to be associated with each exposure, and regressed the WLM-adjusted maternal effect sizes on BW for those SNPs against the effect estimates for the maternal exposure, weighting by the inverse of the variance of the maternal exposure effect estimates. In the same way, we used the WLM-adjusted fetal effects to estimate the causal effect of the offspring's genetic potential on their own BW, and compared the results with the estimated maternal causal effects.

Height and birth weight

We used the WLM-adjusted estimates to investigate the relationship between maternal height and offspring BW. Classical animal experiments²⁶ have demonstrated that larger maternal size can support greater fetal growth. This is supported by observational human data showing that offspring height shifts from being closer to maternal than paternal height percentile in infancy towards mid-parental height in adulthood, the latter reflecting the predominant role of inherited genetic variation²⁷. However several observational studies have provided mixed evidence regarding correlations between maternal or paternal height and offspring BW: some studies show a stronger correlation with maternal than paternal height^{28,29}, which would be consistent with a role for intrauterine effects (since both parents contribute equally to offspring genotype), while others show that maternal height is as strongly correlated with offspring BW as paternal height³⁰⁻³². The MR analysis, using height-associated SNPs as the instrumental variable³³ (**Supplementary Table 14**), estimated that a 1 SD (6cm) higher maternal height is causally associated with a 0.11 SD (95%CI: 0.10, 0.13) higher offspring BW (**Figure 3B**), independent of the direct fetal effects. This estimate was similar in magnitude to that obtained using the WLM-adjusted fetal effects on own BW (0.11 SD (95%CI: 0.09, 0.13)), which reflects the role of inherited height alleles (**Supplementary Table 15**). Both a previous study³⁴ and complementary analysis using transmitted and non-transmitted alleles in mother-offspring pairs (comparison of effects of maternal non-transmitted height alleles with alleles transmitted to offspring in N=3,485 and 4,962 mother-offspring pairs, respectively) estimated a much larger contribution of direct fetal effects than indirect maternal effects to offspring BW (**Supplementary Table 16**), however the sample sizes in both analyses were relatively small. To test whether the maternal height effect might be influencing BW by increasing gestational duration, as previously reported³⁴, we applied the same MR analysis to maternal genotype effects on gestational duration²¹, but found little supportive evidence (P=0.12; **Supplementary Table 15**). The MR results from the current study are consistent with the hypothesis that greater maternal height causally increases BW, and that this effect is independent of the direct BW-raising effect of height alleles inherited by the fetus. For the maternal effect, we cannot rule out causal pathways other than the greater availability of space for fetal growth: causal associations between greater height and more favourable socio-economic position³⁵, for example, could enhance maternal nutritional status and result in higher offspring BW. We also cannot exclude the contribution of assortative mating³⁶ to these results: correlation between maternal and paternal height genotypes could lead to similar maternal and fetal MR estimates.

Glycemic traits and birth weight

We used the WLM-adjusted estimates to assess the causal effect of maternal fasting glucose levels on BW with precision that was not achievable previously²⁴ due to the inability to adjust for direct fetal effects in a large sample. Maternal glucose is a key determinant of fetal growth: it crosses the placenta, stimulating the production of fetal insulin which promotes growth³⁷, and as a consequence, strong, positive associations are seen between maternal fasting glucose, or fetal insulin levels, and offspring BW³⁸. In a randomized clinical trial of women with gestational diabetes mellitus, glucose control was shown to reduce offspring BW³⁹. Therefore, we anticipated detecting a positive causal effect of maternal glucose on offspring BW. Indeed, the MR analysis using 33 fasting glucose-associated SNPs (**Supplementary Table 14**), estimated an 0.18 SD (95%CI: 0.13, 0.23) higher offspring BW

due to 1 SD (0.4mmol/L) higher maternal fasting glucose, independent of the direct fetal effects (**Supplementary Table 15; Figure 3C**). A large part of the genetic variation underlying fasting glucose levels is implicated in pancreatic beta cell function and thus overlaps with the genetics of insulin secretion. To estimate the causal effect of insulin secretion on BW, we used 18 SNPs as instrumental variables that are associated with disposition index (DI), which is a measure of insulin response to glucose, adjusted for insulin sensitivity. Low values of DI are associated with higher T2D risk. Alleles that increase insulin secretion in the mother tend to decrease her glucose levels, which consequently reduces insulin-mediated growth of the fetus. This was reflected in the negative causal estimate from the MR analysis of the effect of maternal DI on offspring BW (-0.17 SD per 1 SD higher maternal DI (95%CI: -0.26, -0.08); **Supplementary Table 15**). In contrast, we estimated that BW was 0.10 SD (95%CI: 0.02, 0.19) higher per 1 SD genetically higher fetal DI (**Methods**), highlighting that genetic variation underlying insulin secretion plays a key role in fetal growth, and suggesting that the genetic effects on DI are similar in fetal and adult life.

BW associations with previously-reported GWAS SNPs for fasting glucose, T2D, insulin secretion and insulin sensitivity loci were directionally consistent with the overall genetic correlations and supported the opposing contributions of fetal versus maternal glucose-raising alleles on BW (**Supplementary Figures 10-13**). Taken together with the WLM-adjusted genetic correlations, the MR results underline the importance of fetal insulin in fetal growth and demonstrate that fetal genetic effects link lower BW with reduced insulin secretion and higher T2D risk in later life⁶. However, further work will be needed to investigate the role of maternal indirect genetic effects in the relationship between high BW and higher future risk of T2D. The latter relationship may be driven by (i) maternal genetic predisposition to T2D resulting in raised glycemia in pregnancy and high offspring BW, then later offspring T2D through inheritance of maternal risk alleles, or (ii) a programming effect of exposure to high maternal glucose on later offspring T2D risk, or (iii) a combination of the two. The proportion of the negative BW-T2D covariance explained by fetal genotype effects on own BW was estimated to be 36% (95%CI: 15, 57; **Supplementary Table 17**), though this is likely an underestimate since current methods cannot adjust for the opposing effects of maternal genotypes.

Blood pressure and birth weight

Observational studies of the relationship between BW and later life BP have produced mixed findings: some studies indicate that lower BW is associated with higher later-life BP and related comorbidities⁴⁰, whereas others have shown that this relationship could be driven by a statistical artifact due to adjusting for current weight^{41,42}. We previously showed that genetic factors account for a large proportion of an association between lower BW and higher BP⁵, but it was not clear whether this was due to direct fetal genotype effects, or indirect maternal effects, or a combination of the two. We explored this contested association further using several complementary analyses. The estimate of the BW-SBP covariance explained was higher when using the maternal genotyped SNP associations with offspring BW (65% (95%CI: 57, 74%)), than when using the fetal genotype associations with own BW (56% (95%CI: 48, 64%); **Supplementary Table 17**). A similar pattern was seen with the BW-DBP covariance (72% (95%CI: 58, 85%) explained using the maternal genotyped SNP associations with offspring BW and 56% (95%CI: 46, 67%) explained using the fetal genotype associations on own BW; **Supplementary Table 17**). Together with the larger maternal than

fetal genetic correlations (**Figure 2**), these results point to the predominant importance of indirect maternal effects of BP genetics on offspring BW (**Supplementary Figures 14 and 15**). In line with this, MR analyses indicated that a 1SD (10mmHg) higher maternal SBP is causally associated with a 0.15 SD (95%CI: -0.19, -0.11) lower offspring BW, independent of the direct fetal effects. In contrast, there was no fetal effect of SBP on their own BW, after adjusting for the indirect maternal effect (-0.01 SD per 10mmHg, 95% CI: -0.05, 0.03; **Supplementary Tables 14 and 15; Figure 3D**). Similar results were seen in the WLM-adjusted MR analyses of DBP on both offspring and own BW.

Estimating the causal effect of BW-lowering intrauterine exposures on offspring SBP

Having established (i) substantial negative genetic covariance between BW and SBP and (ii) indirect causal effects of maternal SBP-raising genotypes on lower offspring BW, a key question is whether maternal SNPs that reduce offspring BW through intrauterine effects are also associated with higher SBP in their adult offspring. Such an association would suggest that the maternal intrauterine effects also cause the later BP effect (i.e. possibly through developmental adaptations) (**Figure 4A; Supplementary Figure 16**). To investigate this possibility, we tested the conditional association between maternal and offspring genetic scores for BW and offspring SBP as measured in 3,886 mother-offspring pairs in the UK Biobank, with sensitivity analyses in 1,749 father-offspring pairs. The fetal genetic score for lower BW was associated with higher offspring SBP, even after adjustment for maternal (or paternal) BW genetic score. However, when adjusted for fetal genotypes, the maternal allele score for lower BW was associated with lower (*not higher*) offspring SBP (**Supplementary Table 18**). Taken together, our results demonstrate that the observed negative correlation between BW and later SBP is driven by (i) the causal effect of higher maternal SBP on lower offspring BW (**Figure 3D**), in combination with (ii) the subsequent transmission of SBP-associated alleles to offspring, which then increase offspring SBP (**Figure 4B**), rather than by long-term developmental compensations to adverse *in utero* conditions.

DISCUSSION

In greatly-expanded GWAS and follow-up analyses of own and offspring BW, we have identified 214 novel association signals and have partitioned the genetic effects on BW into direct fetal and indirect maternal (intrauterine) effects, both for genome-wide significant SNPs, and for SNPs across the genome. Further analyses using these partitioned effects indicated both fetal-specific and maternal-specific mechanisms and tissues involved in the regulation of BW, and also mechanisms with directionally-opposing effects in the fetus and mother (e.g. insulin secretion, fasting glucose).

The variety of phenotypes associated with the identified BW SNPs, and pathways highlighted, illustrate that fetal growth is the result of many different processes⁴³. We used the knowledge that subsets of BW-associated SNPs influence BP while others influence glycemic traits, or height, together with the WLM-adjusted estimates of maternal and fetal effects on BW to achieve a deeper level of insight into the relationships between BW and these adult traits. MR analyses using the WLM-adjusted estimates showed (i) evidence that both direct fetal and indirect maternal effects of height-raising genotypes contribute to higher offspring BW, (ii) that fetal, and not maternal, genotype effects explain the negative genetic correlation between BW and later T2D, and (iii) that the negative genetic correlation between BW and adult SBP is the result of both indirect SBP-raising effects of maternal genotypes reducing offspring BW, and direct effects of fetal genotypes on higher adult SBP. The resolution of maternal vs. fetal effects was higher in these MR analyses than has previously been achieved using analyses of available mother-child pairs⁴⁴, due to greater statistical power. Recently, a number of studies have attempted to use MR methodology to investigate causal links between BW and later T2D⁴⁵⁻⁴⁷. However, such naïve MR analyses using two-sample approaches in unrelated sets of individuals, which do not properly account for the correlation between maternal and fetal genotype effects, may result in erroneous conclusions regarding causality. Future investigations into causal links between BW and later T2D or other disease outcomes will require larger samples than are currently available, that have maternal and offspring genotypes in addition to offspring later-life disease outcomes.

There are some limitations to this study. Although we were able to fit the full SEM at the 305 genome-wide significant SNPs, we were unable to fit the SEM at all SNPs across the genome. We have shown previously how a two degree of freedom test based on this SEM (i.e. where maternal and fetal paths are constrained to zero) can have greater power to detect associated loci, particularly when maternal and fetal genetic effects on the phenotype are similar in magnitude (including situations where the effects operate in opposite directions). However, we are currently unable to fit the SEM nor conduct an equivalent test in a computationally feasible manner across the genome. If such a test were developed, it would provide greater power than the current one degree of freedom tests used in the WLM-adjusted analyses, particularly for SNPs where maternal and fetal genetic effects operate in opposite directions, and could therefore be used for locus detection in future analyses. Additionally, there are a number of limitations relating to the MR analyses. First, the MR results concern BW variation within the normal range and do not necessarily reflect the effects of extreme environmental events (e.g. famine), which may exert qualitatively different effects and produce long-term developmental compensations in

addition to low BW. Additionally, we have assumed a linear relationship between BW and later life traits, which is an oversimplification, particularly for T2D: higher BW is associated with later T2D risk, in addition to lower BW, particularly in populations with a high prevalence of T2D. MR is not well placed to examine the effects of extreme events, or non-linear relationships, and alternative methodology will be necessary to investigate life-course associations in this context. Second, BW is the end marker of a developmental process, with critical periods during the process that may make the fetus particularly sensitive to environmental influences. The MR analyses could therefore be masking effects at certain critical periods. We would need to look at maternal exposures on intrauterine growth trajectories or the specific function of the genetic variants on BW to interrogate this further. Third, we have assumed that genetic variants identified in large GWAS of SBP and glycemic traits in males and non-pregnant females are similarly associated in pregnant women. This assumption is reasonable, given that genetic associations are generally similar in pregnant vs non-pregnant women, though there is some indication that genetic effects on SBP are weaker in pregnancy (see Table 2, eTable 5 and eTable 6f in Tyrrell et al.²⁴). Fourth, we have not investigated the potential gender difference in the associations between BW and later life traits. There is evidence that the association between BW and both T2D⁴⁸ and SBP⁴⁹ is stronger in females than males. However, to perform the MR analyses, we would require male and female-specific effect sizes for each of the exposures, which are currently not available. Finally, we have assumed that the critical period of exposure to maternal indirect genetic effects is pregnancy, and that the estimates do not reflect pre-pregnancy effects on primordial oocytes or post-natal effects⁴⁴. However, since we have used BW-associated SNPs, the maternal effects are most-likely mediated *in utero*. While we cannot rule out postnatal effects⁵⁰, our analysis of offspring SBP associations with BW-associated SNPs in father-child pairs showed different associations compared with mother-child pairs, implying postnatal effects were unlikely.

To conclude, the systematic separation of fetal from maternal genetic effects in a well-powered study has enhanced our understanding of the regulation of BW and of its links with later cardiometabolic health. In particular, we show that the association between lower BW and higher adult BP is attributable to genetic effects, and not to intrauterine programming. In successfully separating fetal from maternal genetic effects and using them in Mendelian randomization analyses, this work sets a precedent for future studies seeking to understand the causal role of the intrauterine environment in later-life health.

ONLINE METHODS

Ethics statement

All human research was approved by the relevant institutional review boards and conducted according to the Declaration of Helsinki. The UK Biobank has approval from the North West Multi-Centre Research Ethics Committee (MREC), which covers the UK. Participants of all studies provided written informed consent. Ethical approval for the ALSPAC study was obtained by the ALSPAC Ethics and Law Committee and the local Research Ethics Committees.

Statistical tests

Details of statistical tests used in the various analyses are reported under the appropriate headings below. All tests were two-sided, unless otherwise stated.

UK Biobank phenotype preparation

The UK Biobank is a study of 502,655 participants⁵¹. A total of 280,315 participants reported their own birth weight (BW) in kilograms at either the baseline visit or at least one of the follow-up visits. Participants reporting being part of a multiple birth were excluded from our analyses (N=7,706). For participants reporting BW at more than one visit (N=11,214), the mean value of the reported BWs was used, and if the mean difference between any 2 time points was >1kg, the participant was excluded (N=74). Data on gestational duration were not available; however, in order to exclude likely pre-term births, participants with BW values <2.5kg or >4.5kg were excluded (N=36,330). The remaining BW values were Z-score transformed separately in males and females for analysis.

Female participants were also asked to report the BW of their first child. A total of 216,839 women reported the BW of their first child on at least one assessment center visit. Values were recorded to the nearest whole pound, and were converted to kilograms for our analyses. Where women reported the BW of the first child at multiple time points (N=11,353) these were averaged and women were excluded if the mean difference between any 2 offspring BW measurements was >1kg (N=31). Women who reported the BW of their first child <2.2kg or >4.6kg were excluded (N=6,333). BW of first child was regressed against age at first birth and assessment center location. Residuals from the regression model were converted to Z-scores for analysis (sex of the first child was not available, so we were unable to calculate sex-specific Z-scores).

UK Biobank ethnicity classification and genome-wide association analysis

We analysed data from the May 2017 release of imputed genetic data from the UK Biobank, a resource extensively described elsewhere⁵¹. Given the reported technical error with non-HRC imputed variants, we focused exclusively on the set of ~40M imputed variants from the HRC reference panel.

In addition to the quality control metrics performed centrally by the UK Biobank, we defined a subset of “white European” ancestry samples. To do this, we generated ancestry informative principal components (PCs) in the 1000 genomes samples. The UK Biobank samples were then projected into this PC space using the SNP loadings obtained from the principal components analysis using the 1000 genomes samples. The UK Biobank participants’ ancestry was classified using K-means clustering centered on the 3 main 1000 genomes populations (European, African, South Asian). Those clustering with the European

cluster were classified as having European ancestry. The UK Biobank participants were asked to report their ethnic background. Only those reporting as either “British”, “Irish”, “White” or “Any other white background” were included in the clustering analysis. In total, 217,397 participants with a valid measure of their own BW and 190,406 women with a valid measure of BW of first child were classified as European and included in analyses. For trans-ethnic analyses all participants with valid phenotypes were included regardless of ancestry (N=227,530 participants with a valid measure of their own BW and N=210,208 with a valid measure of the BW of their first child).

Association analysis was conducted using a linear mixed model implemented in BOLT-LMM v2.3⁵² to account for population structure and relatedness. Only autosomal genetic variants which were common (MAF>1%), passed QC in all 106 batches and were present on both genotyping arrays were included in the genetic relationship matrix (GRM). For the genome-wide association study (GWAS) of the participants’ own BW, genotyping array and year of birth were included as covariates in all models. For the GWAS of the BW of the first child, genotyping array and genotyping release (interim vs. full) were included as covariates in the regression model, and indels, regions of long range LD (as defined in ⁵¹) and SNPs with Hardy-Weinberg equilibrium P-values<1x10⁻⁶ were excluded from the GRM.

GWAS of own birth weight

European ancestry meta-analysis of own birth weight: The European ancestry GWAS meta-analysis of own BW consisted of two components: (i) 80,745 individuals from 35 studies participating in the EGG Consortium from Europe, USA and Australia; and (ii) 217,397 individuals of white European origin from the UK Biobank. Studies from the EGG Consortium conducted genome-wide association analysis of own BW that was Z-score transformed separately in males and females, and adjusted for study-specific covariates, including gestational duration, where available (**Supplementary Table 1**). GWASs were imputed up to the 1000 Genomes⁵³ (1000G) reference panel. We combined the sex-specific BW association summary statistics across the EGG studies in a fixed-effects meta-analysis, implemented in GWAMA⁵⁴, and subsequently combined the resulting summary statistics with the UK Biobank summary statistics using a second fixed-effects meta-analysis (max N=297,142). Variants failing GWAS quality control filters, reported in less than 50% of the total sample size in the EGG component, or with MAF<0.1%, were excluded from the European ancestry meta-analysis. We also performed a fixed-effects meta-analysis of the association summary statistics for 16,095 directly genotyped SNPs on the X-chromosome from the UK Biobank and the meta-analysis of the EGG studies (max N=270,929) using GWAMA⁵⁴. A locus was defined as a gap of ≥500kb between any genome-wide significant SNPs, and the lead SNP within each locus was the SNP with the smallest P-value. The set of lead SNPs from each locus will be referred to as our genome-wide significant SNPs.

We were concerned that self-reported BW as adults in the UK Biobank would not be comparable with that obtained from more stringent collection methods used in the EGG studies. We conducted a heterogeneity test using Cochran’s Q statistic⁵⁵, as implemented in GWAMA⁵⁴, to assess the difference in allelic effects between the European EGG meta-analysis and the European subset of the UK Biobank, and we were unable to detect evidence of heterogeneity at lead SNPs after Bonferroni correction (all P>0.00029;

Supplementary Table 5). However, we acknowledge that the power to detect evidence for heterogeneity using the Cochran’s Q statistic when comparing two groups is low and we use it here to highlight any SNPs with large differences in allelic effects. Although none of the

SNPs reached the Bonferroni corrected threshold, there was an enrichment for low P, with more than double the expected number of SNPs with $P < 0.05$ (18/173; **Supplementary Table 5**). In addition, the UK Biobank lacked information on gestational duration, which could impact the strength of association compared to the results obtained from the EGG studies which adjusted for gestational duration. Therefore, we conducted a further sensitivity analysis to specifically assess the impact of adjustment for gestational duration testing for heterogeneity in allelic effects at lead SNPs between EGG studies which adjusted for gestational duration ($N=43,964$) and the European subset of the UK Biobank. The only locus where the lead SNP showed significant heterogeneity, after Bonferroni correction, was rs1482852 at the *LOC339894/CCNL1* signal ($P_{het}=0.00015$), which was a locus showing the strongest association with own BW and genome-wide significant in both EGG and the UK Biobank components independently.

There is potential for individuals to be in both the UK Biobank and EGG studies (i.e. the same individual in both the UK Biobank and a study within EGG) and this might lead to false positive association signals. We performed a bivariate linkage-disequilibrium (LD) score regression¹⁹ analysis using the European UK Biobank GWAS and European EGG meta-analysis summary statistics of own BW, and observed a regression intercept of 0.0266 (0.0077), indicating that the equivalent of approximately 3,524 individuals were in both GWAS analyses.

Univariate LD score regression⁵⁶ of the European ancestry meta-analysis of own BW estimated the genomic inflation as 1.08, indicating that the majority of genome-wide inflation of the test statistics was due to polygenicity. To assess the impact of this inflation on the European ancestry meta-analysis, we re-calculated the association P-values after adjusting the test statistics for the LD score regression intercept. On the basis of this adjusted analysis, the lead SNP at 22 loci (out of 173) no longer reached genome-wide significance (**Supplementary Table 5**).

Approximate conditional and joint multiple-SNP (COJO) analysis to identify additional independent signals for own birth weight: Approximate COJO analysis¹³ was performed in GCTA⁵⁷ using the European ancestry meta-analysis summary statistics to identify independent association signals attaining genome-wide significance ($P < 5 \times 10^{-8}$). The LD reference panel was made up of 344,246 unrelated UK Biobank participants defined by the UK Biobank as having British ancestry and SNPs were restricted to those present in the HRC reference panel. At each locus, only SNPs labelled by GCTA as “independent” and not in LD with the original lead SNP ($R^2 < 0.05$) were listed as secondary SNPs.

Trans-ethnic meta-analysis of own birth weight: To identify any further independent BW-associated SNPs, we conducted a trans-ethnic meta-analysis combining three components: (i) 80,745 individuals from the European ancestry component within EGG; (ii) 12,948 individuals from nine studies within EGG from diverse ancestry groups: African American, Afro-Caribbean, Mexican, Chinese, Thai, Filipino, Surinamese, Turkish and Moroccan; and (iii) 227,530 individuals of all ancestries from the UK Biobank. The same strategy and variant filtering criteria were applied as in the European meta-analysis of own BW (**Supplementary Figure 1**). None of the lead SNPs showed evidence of heterogeneity in BW allelic effects across the three components after Bonferroni correction (all Cochran’s Q $P > 0.169$; **Supplementary Table 5**). Univariate LD score regression⁵⁶ of the trans-ethnic meta-analysis estimated the genomic inflation as 1.08. After adjustment of the test statistics for the LD

score regression intercept, the lead SNP at 8 loci (out of 11 that were added to our genome-wide significant loci from the trans-ethnic meta-analysis that were not identified in the European meta-analysis) dropped below genome-wide significance (**Supplementary Table 5**).

GWAS of offspring birth weight

European ancestry meta-analysis of offspring birth weight: The European ancestry GWAS meta-analysis of offspring BW consisted of three components: (i) 12,319 individuals from 10 European GWAS imputed up to the HapMap 2 reference panel; and (ii) two European GWAS imputed up to the HRC panel (855 individuals from EFSOCH and 6,687 individuals from ALSPAC); and (iii) 190,406 individuals of white European origin from the UK Biobank. Studies from the EGG Consortium conducted genome-wide association analysis on offspring BW that was Z-score transformed, and adjusted for sex, gestational duration and ancestry informative principal components where necessary, (**Supplementary Table 3**). We then combined the BW association summary statistics across the 10 HapMap 2 imputed EGG studies in a fixed-effects meta-analysis, implemented in GWAMA⁵⁴. We conducted a second European ancestry fixed-effects meta-analysis to combine the association summary statistics from the EGG meta-analysis with the UK Biobank, EFSOCH and ALSPAC (max N=210,267). The same strategy and variant filtering criteria were applied as in the meta-analysis of own BW. We also performed a fixed-effects meta-analysis of the association summary statistics for 18,137 directly genotyped SNPs on the X-chromosome from the UK Biobank and the meta-analysis of the EGG studies (max N=197,093) using GWAMA⁵⁴. None of the lead SNPs showed evidence of heterogeneity in BW allelic effects, after Bonferroni correction (Cochran's Q $P > 0.00060$), between the UK Biobank and EGG studies and there was no enrichment for low P, with only 1/81 SNPs with $P < 0.05$ (**Supplementary Table 5**). Using bivariate LD score regression¹⁹, we observed a regression intercept of 0.0165 (0.0063), indicating that the equivalent of approximately 1,015 individuals were in both the EGG and UK Biobank GWAS analyses of offspring BW.

Univariate LD score regression⁵⁶ of the European ancestry meta-analysis estimated the genomic inflation as 1.05. Similar to the own BW GWAS results, we recalculated the P-values after adjusting the test statistics for this LD score intercept and the lead SNP at 8 loci (out of 81) dropped below genome-wide significance (**Supplementary Table 5**).

Approximate conditional and joint multiple-SNP (COJO) analysis to identify additional independent signals for offspring birth weight: We performed approximate COJO analysis¹³ using the European ancestry meta-analysis summary statistics of offspring BW, using the same reference panel as in the own BW analysis. Similarly to the analysis of own BW, SNPs labelled by GCTA as "independent" and not in LD with the original lead SNP ($R^2 < 0.05$) were listed as secondary SNPs associated with offspring BW.

Trans-ethnic meta-analysis of offspring birth weight: We conducted a trans-ethnic meta-analysis combining three components: (i) 12,319 individuals from 10 European GWAS imputed up to the HapMap 2 reference panel; and (ii) two European GWAS imputed up to the HRC panel (855 individuals from EFSOCH and 6,686 individuals from ALSPAC); and (iii) 210,208 individuals of all ancestry from the UK Biobank. The same strategy and variant filtering criteria were applied as in the European meta-analysis of offspring BW (**Supplementary Figure 2**). None of the lead SNPs showed evidence of heterogeneity in BW

allelic effects, after Bonferroni correction (Cochran's Q $P > 0.00054$), between the UK Biobank and EGG studies; however, there was an enrichment for low P , with 3/14 SNPs with $P < 0.05$ (expected 1; **Supplementary Table 5**). Univariate LD score regression⁵⁶ of the trans-ethnic meta-analysis estimated the genomic inflation as 1.04. We adjusted the test statistics for this LD score regression intercept, and the corresponding adjusted P -values for the lead SNP at 6 loci (out of 14 that were added to our genome-wide significant loci from the trans-ethnic meta-analysis that were not identified in the European meta-analysis) dropped below genome-wide significance (**Supplementary Table 5**).

Colocalization methods

For each signal where we identified different lead SNPs in the GWAS of own BW and offspring BW, we performed co-localization analysis using the method implemented in the "coloc" R package⁵⁸. For each signal, we input the regression coefficients, their variances and SNP minor allele frequencies for all SNPs 500kb up and downstream of the lead SNP from the European meta-analysis. We used the coloc.abf() function to calculate posterior probabilities that the own BW and offspring BW lead SNPs were independent (H_3) or shared the same associated variant (H_4). Default values were used for the prior probabilities in the coloc.abf() function. We call variants the same signal if the H_4 posterior probability was greater than 0.50, and different signals if the H_3 posterior probability was greater than 0.50.

Estimation of genetic variance explained

Firstly, we estimated the proportion of BW variance explained by fetal genotypes, maternal genotypes and the covariance between the two at the 278 genome-wide significant signals in the Norwegian Mother and Child Cohort Study (MoBa-HARVEST; $N=13,934$ mother-offspring pairs; <https://www.fhi.no/en/studies/moba/>). This sample was independent of samples contributing to the discovery meta-analyses, apart from a small potential overlap with mothers from the MoBa-2008 sample that was included in the GWAS of offspring BW (affecting a maximum of 0.07% of the meta-analysis sample). For the 27 signals that had a maternal and fetal SNP, the fetal SNP was used in the analysis. This was to avoid any collinearity in the model due to the high correlation between the maternal and fetal SNPs. One SNP, rs77553582, was not available in MoBa-HARVEST, so we used a proxy SNP, rs2024344, in the analysis ($r^2=0.998$ between rs77553582 and rs2024344). We excluded multiple births, babies of non-European descent, born before 37 weeks of gestation, born with a congenital anomaly or still-born. BW was Z-score transformed and all models were adjusted for sex, gestational duration and the first 4 ancestry informative principal components. We conducted a linear regression analysis in R⁵⁹ using 13,934 mother-offspring pairs where offspring BW was regressed on the maternal and fetal genotypes at all 278 SNPs simultaneously. The proportion of variance explained by fetal genotypes at the 278 genome-wide significant signals was calculated as:

$$\sum_{i=1}^{278} \frac{2p_i(1-p_i)\hat{\beta}_{fi}^2}{\text{var}(BW)}$$

Where p_i is the effect allele frequency of the i^{th} SNP, $\hat{\beta}_{fi}$ is the regression coefficient for the effect of the offspring's genotype at the i^{th} SNP on offspring BW and $\text{var}(BW)$ is the variance of offspring BW (which is approximately 1 as BW was Z-score transformed). A similar formula was used to calculate the variance explained by maternal genotypes:

$$\sum_{i=1}^{278} \frac{2p_i(1-p_i)\hat{\beta}_{m_i}^2}{var(BW)}$$

Where $\hat{\beta}_{m_i}$ is the regression coefficient for the effect of the maternal genotype at the i^{th} SNP on offspring BW. Finally, a similar formula was used to calculate twice the covariance:

$$\sum_{i=1}^{278} \frac{2p_i(1-p_i)\hat{\beta}_{f_i}\hat{\beta}_{m_i}}{var(BW)}$$

Secondly, we used maternal genome-wide complex trait analysis¹¹ (M-GCTA) to estimate the proportion of variance explained in BW by genome-wide SNPs, or SNPs they tag, in the fetal genome, the maternal genome, the covariance between the two or environmental factors in MoBa-HARVEST. The same phenotype was used as in the previous analysis and the model was adjusted for sex and gestational duration. Mothers or offspring were excluded if they were related to others in the sample, using a genetic relationship cut-off 0.025, leaving N=7,910 mother-offspring pairs available for analysis.

Identifying eQTL linked genes

To identify specific eQTL linked genes, we used the FUSION tool⁶⁰ on the v6p release of the GTEx data¹⁵. FUSION is a gene-based data aggregation and integration method which incorporates information from gene-expression data and GWAS data to translate evidence of association with a phenotype from the SNP-level to the gene. Only gene level results from the adjusted model were taken forward for consideration. The threshold for statistical significance was estimated using the Bonferroni method for multiple testing correction across all tested tissues (tissue N=44, $P < 6 \times 10^{-7}$). Each of the genes implicated by this analysis survived multiple test correction and were independent from other proximal genes tested in a joint model.

Placenta eQTL look ups

We annotated genome-wide significant BW-associated SNPs with gene expression data (293/305 SNPs available) from placental samples of European ancestry from the Rhode Island Child Health Study¹⁶ (RICHs; N=123 with fetal genotype, including 71 with BW appropriate for gestational age, 15 small for gestational age, and 37 large for gestational age). We annotated genome-wide significant BW-associated SNPs on our list that had genome-wide empirical FDR<0.01 for association with one or more transcripts and $r^2 > 0.7$ with a lead eQTL SNP.

TAD pathways

Topologically associating domains (TAD) pathway analysis was performed using software described in Way *et al.*¹⁷. Briefly, the software uses publicly available TAD boundaries, identified in human embryonic stem cells and fibroblasts using a Hidden Markov Model¹⁸, to prioritize candidate genes at GWAS SNPs. These TAD boundaries are stable across different cell types and therefore can be used to identify genomic regions where non-coding causal variants will most likely impact tissue-independent function.

Structural equation model for estimating adjusted maternal and fetal effects of the genome-wide significant variants

The structural equation modelling (SEM) approach used to estimate maternal and fetal effects that are independent of the fetal and maternal genotype respectively has been described elsewhere¹². Briefly, to estimate the parameters for the SEM-adjusted fetal and maternal effects on BW, we use three observed variables available in the UK Biobank; the participant's genotype, their own self-reported BW, and in the case of the UK Biobank women, the BW of their first child (**Supplementary Figure 17**). Additionally, the model comprises two latent (unobserved) variables, one for the genotype of the UK Biobank participant's mother and one for the genotype of the participant's offspring. From biometrical genetics theory, these latent genetic variables are correlated 0.5 with the participant's own genotype, so we fix the path coefficients between the latent and observed genotypes to be 0.5. Participants who only report their own BW (including males), contribute directly to estimation of the fetal effect of genotype on BW and also indirectly to estimation of the maternal effect on BW since their observed genotype is correlated with their mother's unmeasured latent genotype at the same locus. Similarly, summary statistics from the EGG meta-analysis of the unadjusted fetal effect (i.e. the European GWAS meta-analysis of own BW) can be incorporated into the model in this manner. Participants who report only their offspring's BW (including mother's reporting BW of their male offspring), contribute directly to estimation of the maternal effect on BW and indirectly to the estimate of the fetal effect on BW, since their observed genotype is correlated with their offspring's latent genotype at the same locus. Again, summary statistics from the EGG meta-analysis of the unadjusted maternal effect (i.e. the European GWAS meta-analysis of offspring BW) can be incorporated into the model this way. These five components are fit to the five subsets of data (i.e. the UK Biobank participants with complete data, the UK Biobank participants with their own BW and genotype data only, EGG summary statistics for the unadjusted fetal effect of genotype on BW, the UK Biobank participants with their offspring's BW and maternal genotype only and EGG summary statistics for the unadjusted maternal effect of genotype on BW) and then the likelihoods from each subset are combined. In addition to fitting the SEM to estimate the SEM-adjusted maternal and fetal effects, we fit a second model constraining the maternal and fetal effects to be zero and conducted a two degree of freedom Wald test to assess any effect of the SNP on BW. There is likely to be measurement error in the BW data in the UK Biobank, as well as some of the EGG studies, due to difficulty recalling BW. Additionally, the women in UK Biobank were asked to recall their offspring BW to the nearest pound. We have shown using simulations that both random measurement error (for example, due to difficulty in recall) and measurement error in offspring BW due to rounding to the nearest pound do not have a substantial influence on the estimation of either the maternal or fetal effects (see Warrington et al.¹²). We therefore do not think that the imprecision of the UK Biobank BW data will substantially influence the results of downstream analyses.

The SEM was fit to data from 210 genome-wide significant fetal and 105 maternal SNPs from the GWAS meta-analysis; rs77553582, was only available in the GWAS of own BW from the EGG consortium so the SEM was not fit for this SNP (**Supplementary Figure 4**). In order to identify a subset of unrelated individuals in the UK Biobank (as the SEM cannot easily account for relatedness), we generated a genetic relationship matrix in the GCTA software package⁵⁷ (version 1.90.2) and excluded one of every pair of related individuals with a genetic relationship greater than 9.375% (i.e. approximately half-way between third and

fourth degree relatives). This gave us a subset of 382,001 unrelated individuals of European descent, after the same exclusions were made as in the GWAS, of which 85,518 individuals had reported their own BW and their offspring's BW, 98,235 individuals reported their own BW only, and 73,981 reported their offspring's BW only (the remaining 124,267 unrelated European individuals reported neither so were excluded from the analysis). We fit linear regression models to BW and offspring BW in the European, unrelated subset of individuals and adjusted for sex (own BW only), assessment centre and the top 40 ancestry informative principal components provided by the UK Biobank to account for any remaining population substructure. The residuals from this regression models were Z-score transformed for analysis. Because we included the summary statistics from the meta-analysis of the EGG studies, rather than the individual level data, we were unable to account for the small subset individuals who contributed to both the own BW and offspring BW GWAS meta-analyses. Based on the results from simulations (not shown), we expect that this non-independence will result in very slightly smaller standard errors and increased type 1 error rate, particularly for the fetal effect which is estimated from a larger sample size than was available to estimate the maternal effect. Therefore, we conducted a sensitivity analysis that first excluded EGG studies from the meta-analysis of own BW that contributed to both GWAS meta-analyses of own and offspring BW (e.g. ALSPAC), and then refitted the non-overlapping data in the SEM; these results are presented in **Supplementary Table 19**. For the four genome-wide significant SNPs identified on the X chromosome, we fit a slightly different SEM due to males having double the expected genetic variance at X linked loci compared to females. We did not incorporate summary statistics from the EGG consortium (since GWAS results were not stratified according to sex), so the model only includes the individual level data from the UK Biobank (additional details on the X chromosome analysis are provided in the **Supplementary Material** and **Supplementary Figure 18**). We used the estimates from the SEM to classify SNPs into the following five categories; 1) **fetal only**: the 95% confidence interval surrounding the fetal effect estimate does not overlap zero and does not overlap the 95% confidence interval around the maternal effect estimate. Additionally, the 95% confidence surrounding the maternal effect estimate overlaps zero; 2) **maternal only**: the 95% confidence interval surrounding the maternal effect estimate does not overlap zero and does not overlap the 95% confidence interval around the fetal effect estimate. Additionally, the 95% confidence surrounding the fetal effect estimate overlaps zero; 3) **fetal and maternal, effects going in the same direction**: the 95% confidence intervals around both the maternal and fetal effect estimates do not overlap zero, and their effect is in the same direction; 4) **fetal and maternal, effects going in opposite direction**: the 95% confidence intervals around both the maternal and fetal effect estimates do not overlap zero, and their effects are in opposite directions; and 5) **unclassified**: SNPs that do not fall into any of these categories, and therefore the 95% confidence intervals around the maternal and fetal effect estimates overlap, and at least one overlaps zero.

Meta-analysis of maternal and fetal effects from a conditional regression analysis in mother-offspring pairs

We conducted conditional association analyses for all 305 genome-wide significant SNPs in 18,873 mother-offspring pairs from three studies (MoBa-HARVEST, ALSPAC and EFSOCH) adjusting for both maternal and offspring genotype and combined the summary statistics for each SNP in a fixed effects meta-analysis using METAL⁶¹. We compared the estimates of

the maternal and fetal effects of this meta-analysis to the SEM-adjusted maternal and fetal effects using a heterogeneity test, and the results are presented in **Supplementary Table 6**.

Approximation of the SEM for genome-wide analyses

The SEM is computationally intensive to fit, making it difficult to run on all SNPs across the genome. Therefore, we developed an approximation of the SEM using a linear transformation of the BW values and ordinary least squares linear regression, which we refer to as the weighted linear model adjusted (WLM-adjusted) analyses. The full details of the derivation are provided in the **Supplementary Material**. Briefly, from ordinary least squares regression we know that the estimated fetal effect size from the GWAS of own BW, $\hat{\beta}_{f_{unadj}}$, is calculated by dividing the sample covariance between BW and SNP by the sample variance of the SNP. Similarly, the estimated maternal effect from the GWAS of offspring BW, $\hat{\beta}_{m_{unadj}}$, is calculated by dividing the sample covariance between offspring BW and SNP by the sample variance of the SNP. It follows that an estimate of the fetal effect adjusted for the maternal genotype is (see **Supplementary Material** for full derivation):

$$\hat{\beta}_{f_{adj}} = -\frac{2}{3}\hat{\beta}_{m_{unadj}} + \frac{4}{3}\hat{\beta}_{f_{unadj}}$$

and an estimate of the maternal effect adjusted for the fetal genotype is:

$$\hat{\beta}_{m_{adj}} = \frac{4}{3}\hat{\beta}_{m_{unadj}} - \frac{2}{3}\hat{\beta}_{f_{unadj}}$$

If the model is truly linear, then the same estimates can be obtained by transforming the reported BWs rather than the regression coefficients⁶². Similar to the SEM analyses, BW Z-scores in the UK Biobank participants were calculated from residuals of a regression model adjusting for sex (own BW only) and assessment centre, after the same exclusions were made as in the GWAS. For the UK Biobank participants who reported both their own BW and the BW of their offspring (N=101,541), we combined their BW Z-scores using the above formulae and conducted a GWAS in BOLT-LMM⁵² to directly estimate the WLM-adjusted fetal and maternal effects for each SNP (see **Supplementary Figure 19** for a flow diagram of the full analysis pipeline). For the UK Biobank participants who only reported their own BW (N=115,070), we conducted a GWAS of their own BW Z-score in BOLT-LMM to estimate the unadjusted fetal effect for each SNP and then meta-analyzed the results with the unadjusted fetal effect estimates from the EGG consortium using a fixed-effects, inverse-variance weighted meta-analysis in METAL⁶¹. We followed the same procedure using participants who only reported their offspring's BW in the UK Biobank (N=88,846) and meta-analyzed the unadjusted maternal effect estimates with those from the EGG consortium. The UK Biobank sample sizes used in this analysis are larger than those used in the SEM as the GWAS analyses are conducted in BOLT-LMM and can therefore account for the complex cryptic relationships between individuals. To get the WLM-adjusted maternal and fetal effect estimates, we combined the meta-analysis results of the unadjusted maternal and fetal effects for each SNP using the formulae above and their corresponding standard errors (see **Supplementary Material**). Finally, we conducted another fixed-effects, inverse-variance weighted meta-analysis to combine the WLM-adjusted maternal and fetal effect estimates from the UK Biobank participants with both BW measures and the combined WLM-adjusted effect estimates from the UK Biobank and EGG meta-analysis. A comparison of the results using this WLM method and the full SEM for the genome-wide significant SNPs is presented in **Supplementary Figure 8**.

Gene expression integration

In order to identify which tissue types were most relevant to genes involved in BW, we applied LD score regression to specifically expressed genes (“LDSC-SEG”)²⁰. We used the summary statistics from the GWAS meta-analysis of own and offspring BW and the WLM-adjusted meta-analyses, where the summary statistics from the WLM-adjusted meta-analyses were used to obtain tissue specific enrichments un-confounded by maternal and fetal genetic sharing. The method has been described previously²⁰, but in brief it takes each tissue, ranking genes by a t-statistic for differential expression, using sex and age as covariates, and excluding all samples in related tissues. It then takes the top 10% of ranked genes, and makes a genome annotation including these genes (exons and introns) plus 100kb on either side. Finally, it uses stratified LD score regression to estimate the contribution of this annotation to per-SNP BW heritability, adjusting for all categories in the baseline model. We computed significance using a block jackknife over SNPs, and corrected for the number of tissues tested.

Gene-set enrichment analysis (MAGENTA)

Pathway-based associations using summary statistics from the GWAS meta-analysis of own and offspring BW and WLM-adjusted meta-analysis for both the maternal and fetal effect were tested using MAGENTA⁶³. Briefly, the software maps each gene to the SNP with the lowest P-value within a 110kb upstream and 40kb downstream window. This P-value is corrected for factors such as SNP density and gene size using a regression model. Genes within the HLA region were excluded. The observed number of gene scores within a given pathway with a ranked gene score above a given threshold (95th or 75th percentile) was calculated. This statistic was compared with 1,000,000 randomly permuted pathways of the same size to calculate an empirical P-value for each pathway. We considered pathways with false discovery rate (FDR) < 0.05 to be of interest. The 3,230 biological pathways tested were from the BIOCARTA, Gene Ontology, KEGG, PANTHER and READTOME databases along with a small number of custom pathways.

Gestational duration associations

We extracted the 305 genome-wide significant BW-associated SNPs from the summary statistics in a recent GWAS of gestational duration²¹. The full table of 23andMe summary statistics was obtained directly from 23andMe. For BW SNPs that were also associated with gestational duration ($P < 1.6 \times 10^{-4}$, corrected for 305 tests), we followed them up in 13,206 mother-child pairs from the MoBa-HARVEST, ALSPAC and EFSOCH studies. Preterm births (gestational duration < 37 weeks) were removed before analysis, and gestational duration and BW were both z-score transformed. We conducted linear regression analyses to test the association between maternal or fetal genotype (unadjusted genotype effects) and gestational duration, BW or gestational duration adjusted for BW. Additionally, we conducted linear regression analyses for the same three outcomes including both the maternal and fetal genotypes (adjusted effects). The association analysis results were combined using inverse variance weighted meta-analysis. We also combined the unadjusted maternal SNP-gestational duration associations with the 23andMe summary statistics from Zhang *et al.*²¹ using P value based meta-analysis implemented in METAL⁶¹.

Association between birth weight-associated SNPs and a variety of traits in the UK Biobank

We performed GWAS on 78 traits in the UK Biobank using BOLT-LMM in an analogous way to analysis of own BW. Association statistics for the 305 genome-wide significant BW-associated SNPs were then extracted from the results. Phenotype definitions for the 78 traits are described in Frayling *et al.*⁶⁴. Additionally, for the 305 genome-wide significant BW-associated SNPs, and those in high LD with the 305 SNPs ($r^2 > 0.8$), we searched the NHGRI GWAS catalog (<https://www.ebi.ac.uk/gwas/>; accessed 16th January 2018) for reported GWAS associations with other traits. These are reported in **Supplementary Table 13**.

Linkage-Disequilibrium (LD) score regression

LD score regression was used to estimate the genetic correlation between two traits/diseases and has been described in detail elsewhere¹⁹. Briefly, the LD score is a measure of how much genetic variation each variant tags; so if a variant has a high LD score then it is correlated with many nearby variants. Variants with high LD scores are more likely to tag true signals and hence provide greater chance of overlap with genuine signals between GWAS. The method uses summary statistics from the GWAS meta-analyses of BW and the other traits of interest, calculates the cross-product of test statistics at each SNP, and then regresses the cross-product on the LD Score. Bulik-Sullivan *et al.*¹⁹ show that the slope of the regression is a function of the genetic correlation between traits. Individuals contributing to the summary statistics of both GWAS meta-analyses, and population stratification within either GWAS, will only influence the intercept of the regression and therefore not bias the genetic correlation.

We used LDHub⁶⁵ (ldsc.broadinstitute.org/) to perform LD score regression between BW and a large range of traits and diseases. LDHub is a centralized database which contains curated summary statistics from GWAS analyses of over 775 traits and diseases, including the recent release of summary statistics from GWAS analyses of many phenotypes in the UK Biobank (<http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank>). Due to the different LD structure across ancestry groups, the summary statistics from the European only BW analyses were uploaded to LDHub and genetic correlations were calculated for all available phenotypes. We conducted four separate analyses in LDHub: one for the GWAS of own BW, one for the GWAS of offspring BW, one for the WLM-adjusted fetal effect on own BW and the final one for the WLM-adjusted maternal effect on offspring BW.

To calculate the genetic correlation between the maternal and fetal effect estimates from the unadjusted and WLM-adjusted analyses, and also between gestational duration and the WLM-adjusted maternal and fetal effects, we used the scripts provided by the developer (<https://github.com/bulik/ldsc>).

Mendelian randomization analyses of maternal and fetal exposures on offspring birth weight

Two sample Mendelian randomization analyses were performed for a number of exposures with own BW or offspring BW as outcomes. The exposures included height (SD units, where 1SD = 6cm), fasting glucose (SD units, where 1 SD = 0.4mmol/L), disposition index of insulin secretion (calculated from oral glucose tolerance test (OGTT) results as Corrected Insulin Response x 10,000 / $\sqrt{\text{Fasting Plasma Glucose} \times \text{Fasting Insulin} \times \text{Mean Glucose during}}$

OGTT x Mean Insulin During OGTT)⁶⁶, insulin sensitivity (calculated as fasting insulin adjusted for BMI) and systolic and diastolic blood pressure (mmHg). The SNP-exposure associations were taken from external studies (**Supplementary Table 14**). The SNP-outcome associations were taken from the current European GWAS meta-analyses of own BW, offspring BW, WLM-adjusted fetal effect on own BW and WLM-adjusted maternal effect on offspring BW. Two sample Mendelian randomization regresses effect sizes of SNP-outcome associations against effect sizes of SNP-exposure associations, with an inverse-variance weighted (IVW) analysis giving similar results to the commonly used two-stage least squares analysis in a single sample⁶⁷. We performed several sensitivity analyses to assess the impact of genetic pleiotropy on the causal estimates including MR-Egger⁶⁸, Weighted Median (WM)⁶⁹ and Penalized Weighted Median (PWM)⁶⁹ approaches (see **Supplementary Table 15** for results). Details of the R code for the MR analyses are provided elsewhere^{68,69}. Due to the strong negative correlation between estimates of the maternal and fetal genetic effects on BW, we conducted simulations to confirm that this correlation did not bias the results of downstream MR analyses; these simulations are described in the **Supplementary Material**.

Transmitted/non-transmitted allele scores in ALSPAC

Allelic transmission was determined for 4,962 mother/offspring pairs in ALSPAC. We first converted maternal and fetal genotypes into best guess genotypes where SNPs of interest had been imputed. Where one or both of the mother/offspring pair were homozygous, allelic transmission is trivial to determine. Where both mother and offspring were heterozygous for the SNP of interest we used phase imputation generated using SHAPEIT2⁷⁰ to examine the haplotypes in the region of the SNP of interest to determine allelic transmission. Weighted allele scores were then generated for maternal non-transmitted, shared (maternal transmitted) and paternally inherited fetal alleles for systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, insulin secretion and insulin sensitivity. Associations were tested between the weighted allele scores and BW.

Covariance between BW and adult traits explained by genotyped SNPs

The genetic and residual covariance between BW and several quantitative and/or disease phenotypes was calculated in the UK Biobank in the BOLT-LMM⁵² implementation of the REML method, using directly genotyped SNPs. We included 215,444 individuals with data on own BW and 190,406 with data on offspring BW. All individuals were classified as being of European ancestry. SNPs with minor allele frequency < 1%, evidence of deviation from Hardy-Weinberg equilibrium ($P \leq 1 \times 10^{-6}$) or overall missing rate > 0.015 were excluded, resulting in 524,307 SNPs for analysis. Ninety-five per cent confidence intervals for the proportion of covariance explained by variants directly genotyped were calculated as $g_{cov}/(g_{cov}+r_{cov}) \pm 1.96 * g_{cov}SE/abs(g_{cov}+r_{cov})$ where g_{cov} is genetic covariance, r_{cov} is residual covariance and $g_{cov}SE$ is the standard error for g_{cov} and abs is the absolute value. Details of the phenotype preparation for the adult traits is provided in the **Supplementary Material**.

Testing for association between maternal SNPs associated with offspring birth weight and later-life offspring blood pressure

Using the UK Biobank, we tested whether maternal SNPs associated with offspring BW were also associated with offspring blood pressure in later life. The UK Biobank released kinship

information generated in KING⁷¹, which included the kinship coefficients and IBS0 estimates. We defined parent/offspring pairs using the kinship coefficient and IBS0 cut-offs recommended in Manichaikul *et al.*⁷¹. There were 6,276 parent/offspring pairs, of which 5,901 were of European descent and 5,635 unique pairs with blood pressure data (for parents who had multiple offspring with blood pressure data, only the oldest offspring was included in the analysis); 3,886 mother/offspring pairs and 1,749 father/offspring pairs. We tested the relationship between unweighted allelic scores of BW-associated SNPs in mothers and offspring SBP (see **Supplementary Material** for SBP phenotype preparation) before and after adjusting for offspring genotypes at the same loci. We examined unweighted allelic scores consisting of all autosomal genome-wide significant BW-associated SNPs available in the UK Biobank (300 SNPs), 103 autosomal SNPs that showed evidence of a maternal effect, and a subset of 44 autosomal SNPs that showed evidence only of maternal effects on BW. We also looked at the SNPs previously associated with SBP (**Supplementary Table 14**) as a sensitivity analysis to rule out the possibility of postnatal pleiotropic effects of SNPs contaminating our results, we also tested the relationship between allelic scores of BW-associated SNPs in fathers and offspring SBP after adjusting for offspring genotype. All analyses were adjusted for offspring age at SBP measurement, sex and assessment center.

Data availability

The genotype and phenotype data are available upon application from the UK Biobank (<http://www.ukbiobank.ac.uk/>). Individual cohorts participating in the EGG consortium should be contacted directly as each cohort has different data access policies. GWAS summary statistics from this study are available on publication via the EGG website (<https://egg-consortium.org/>).

Figures:

Figure 1: Structural equation modelling (SEM)-adjusted fetal and maternal effects for the 289 genome-wide significant SNPs that were identified in the GWAS of either own birth weight (BW; left panel) or offspring BW (right panel) with minor allele frequency greater than 5%. The colour of each point indicates the SEM-adjusted fetal effect on own BW association P-value and the shape of each point indicates the SEM-adjusted maternal effect on offspring BW association P-value. SNPs which are labelled with the name of the closest gene are those which were identified in the GWAS of own BW but whose effects are mediated through the maternal genome (left panel) and SNPs that were identified in the GWAS of offspring BW but whose effects are mediated through the fetal genome (right panel). SNPs are aligned to the BW increasing allele from the GWAS.



Figure 2: Genome-wide genetic correlation between birth weight (BW) and a range of traits and diseases in later life. Genetic correlation (r_g) and corresponding 95% confidence intervals between BW and the traits were estimated using linkage disequilibrium (LD) score regression in LD Hub. Genetic correlations were estimated from the summary statistics of the weighted linear model (WLM)-adjusted fetal genome-wide association study (GWAS; WLM-adjusted fetal effect on own BW) and the WLM-adjusted maternal GWAS (WLM-adjusted maternal effect on offspring BW). The genetic correlation estimates are colour coded according to their intensity and direction (red for positive correlation and blue for negative correlation). HOMA-B/IR, homeostasis model assessment of beta-cell function/insulin resistance; HbA1c, hemoglobin A1c; ADHD, attention deficit hyperactivity disorder. See **Supplementary Table 10** for the references for each of the traits and diseases displayed and the genetic correlation results for other traits and diseases.




Figure 3. Mendelian randomization to assess the causal effect of maternal intrauterine exposures on offspring birth weight (adapted from Lawlor et al.⁴⁴)

A. Diagram demonstrating how Mendelian randomization may be used to assesses the causal effect of a maternal exposure on offspring birth weight (BW). The analysis assumes that: (i) maternal genotype (instrumental variable, IV) is robustly associated with maternal (intrauterine) exposure; (ii) confounders of the maternal exposure-offspring outcome association are not associated with the maternal genetic IV; (iii) the maternal genetic IV is only associated with offspring BW through its association with the maternal intrauterine exposure, and through no other pathway. Since maternal and fetal genotypes are correlated ($r = 0.5$), it is essential to account for the offspring genotype in this analysis.

The continuous, thin arrow represents the relationship between the genetic instrument and intrauterine exposure. The dashed arrows represent potential confounding via maternal characteristics. The dotted arrows represent potential violation of assumption 3 via the offspring genotype. The thick arrow represents the causal effect of interest estimated in Mendelian randomization analyses, after accounting for offspring genotype effects.


B. Higher offspring BW is caused both by direct fetal genetic effects of height-raising alleles and indirect effects of maternal height-raising alleles. Maternal indirect effects of height-raising alleles may increase offspring BW by increasing the space available for growth, but we cannot rule out alternative pathways e.g. the contribution of assortative mating, which would cause the maternal indirect association estimates to be correlated with direct fetal effects.

C. Higher maternal fasting glucose levels are causally associated with higher offspring BW. Conversely, in the offspring, a genetic score of alleles known to raise adult fasting glucose levels is associated with lower BW, indicating that these alleles have opposite maternal and fetal effects on BW. This is likely due to their effects on insulin: variants that lower maternal insulin levels lead to higher maternal glucose, which crosses the placenta and stimulates fetal insulin-mediated growth. However, the same variants in the fetus cause lower fetal insulin levels, and consequently, reduced fetal insulin-mediated growth.


D. Higher maternal blood pressure is causally associated with lower offspring BW. After adjusting for maternal effects, there was no evidence of an effect of the offspring's own SBP genetic score on their own BW.

SEP, socio-economic position; BW, birth weight; FPG, fasting plasma glucose; SBP, systolic blood pressure. 1 SD of BW = 484g^{9,44}


A



B



C



D




Figure 4. Mendelian randomization to assess the causal effect of intrauterine growth on offspring adult outcomes, using maternal intrauterine exposures that influence fetal growth.


A. Diagram demonstrating how Mendelian randomization may be used to assesses the causal effect of intrauterine exposures that affect fetal growth on later-life offspring outcomes. The analysis assumptions are the same as in any Mendelian randomization analysis (see **Figure 3**). The instrumental variable should be associated with offspring birth weight (BW) independently of offspring genotype, so it is again essential to adjust the analysis for the offspring genotype.

The continuous, thin, arrow represents the relationship between the genetic instrument and intrauterine exposure. The long-dashed arrows denote the (maternal and possibly fetal) genotype associations with BW; these arrows highlight the assumption that the genetic variation is influencing the offspring adult outcome via intrauterine growth pathways, not BW. The short-dashed arrows represent potential confounding via maternal and offspring characteristics. The dotted arrow represents potential violation of assumption 3 of Mendelian randomization analysis (see **Figure 3** legend) via the offspring genotype. The thick arrow represents the causal effect of interest estimated in Mendelian randomization analyses, after accounting for offspring genotype effects.

We have not specifically conducted this Mendelian randomization analysis as we do not have effect estimates for the SNP-maternal intrauterine exposures influencing fetal growth. However, we have used the presence/absence and direction of association in 3,886 mother-offspring pairs from the UK Biobank to indicate whether the intrauterine environment was causing changes in adult SBP (see **Supplementary Table 18** for full results).

B. Taken together, our results demonstrate that the observed negative correlation between BW and later SBP may be driven by the causal effect of higher maternal SBP on lower offspring BW (red arrow), in combination with the subsequent transmission of SBP-associated alleles to offspring (green arrow), which then increase offspring SBP, rather than by long-term developmental compensations to adverse *in utero* conditions.

SEP, socio-economic position; BW, birth weight; SBP, systolic blood pressure.



References

- 1 Barker, D. J. *et al.* Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. *Diabetologia* **36**, 62-67 (1993).
- 2 Martin-Gronert, M. S. & Ozanne, S. E. Mechanisms underlying the developmental origins of disease. *Reviews in endocrine & metabolic disorders* **13**, 85-92, doi:10.1007/s11154-012-9210-z (2012).
- 3 Lumey, L. H., Stein, A. D. & Susser, E. Prenatal famine and adult health. *Annual review of public health* **32**, 237-262, doi:10.1146/annurev-publhealth-031210-101230 (2011).
- 4 Ben-Shlomo, Y. & Smith, G. D. Deprivation in infancy or in adult life: which is more important for mortality risk? *Lancet* **337**, 530-534 (1991).
- 5 Horikoshi, M. *et al.* Genome-wide associations for birth weight and correlations with adult disease. *Nature* **538**, 248-252, doi:10.1038/nature19806 (2016).
- 6 Hattersley, A. T. & Tooke, J. E. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. *Lancet* **353**, 1789-1792, doi:10.1016/s0140-6736(98)07546-1 (1999).
- 7 Beaumont, R. N. *et al.* Genome-wide association study of offspring birth weight in 86 577 women identifies five novel loci and highlights maternal genetic effects that are independent of fetal genetics. *Hum Mol Genet* **27**, 742-756, doi:10.1093/hmg/ddx429 (2018).
- 8 Horikoshi, M. *et al.* New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. *Nat Genet* **45**, 76-82, doi:10.1038/ng.2477 (2013).
- 9 Freathy, R. M. *et al.* Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. *Nat Genet* **42**, 430-435, doi:10.1038/ng.567 (2010).
- 10 Hattersley, A. T. *et al.* Mutations in the glucokinase gene of the fetus result in reduced birth weight. *Nat Genet* **19**, 268-270, doi:10.1038/953 (1998).
- 11 Eaves, L. J., Pourcain, B. S., Smith, G. D., York, T. P. & Evans, D. M. Resolving the effects of maternal and offspring genotype on dyadic outcomes in genome wide complex trait analysis ("M-GCTA"). *Behavior genetics* **44**, 445-455, doi:10.1007/s10519-014-9666-6 (2014).
- 12 Warrington, N. M., Freathy, R. M., Neale, M. C. & Evans, D. M. Using structural equation modelling to jointly estimate maternal and fetal effects on birthweight in the UK Biobank. *International journal of epidemiology*, doi:10.1093/ije/dyy015 (2018).
- 13 Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* **44**, 369-375, s361-363, doi:10.1038/ng.2213 (2012).
- 14 Kemp, J. P. *et al.* Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. *Nat Genet* **49**, 1468-1475, doi:10.1038/ng.3949 (2017).
- 15 GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science (New York, N.Y.)* **348**, 648-660, doi:10.1126/science.1262110 (2015).

- 1531 16 Peng, S. *et al.* Expression quantitative trait loci (eQTLs) in human placentas suggest
1532 developmental origins of complex diseases. *Hum Mol Genet* **26**, 3432-3441,
1533 doi:10.1093/hmg/ddx265 (2017).
- 1534 17 Way, G. P., Youngstrom, D. W., Hankenson, K. D., Greene, C. S. & Grant, S. F.
1535 Implicating candidate genes at GWAS signals by leveraging topologically associating
1536 domains. *European journal of human genetics : EJHG* **25**, 1286-1289,
1537 doi:10.1038/ejhg.2017.108 (2017).
- 1538 18 Dixon, J. R. *et al.* Topological domains in mammalian genomes identified by analysis
1539 of chromatin interactions. *Nature* **485**, 376-380, doi:10.1038/nature11082 (2012).
- 1540 19 Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and
1541 traits. *Nat Genet* **47**, 1236-1241, doi:10.1038/ng.3406 (2015).
- 1542 20 Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies
1543 disease-relevant tissues and cell types. *Nat Genet* **50**, 621-629, doi:10.1038/s41588-
1544 018-0081-4 (2018).
- 1545 21 Zhang, G. *et al.* Genetic Associations with Gestational Duration and Spontaneous
1546 Preterm Birth. *The New England journal of medicine* **377**, 1156-1167,
1547 doi:10.1056/NEJMoa1612665 (2017).
- 1548 22 Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
1549 contribute to understanding environmental determinants of disease? *International
1550 journal of epidemiology* **32**, 1-22 (2003).
- 1551 23 Smith, G. D. *et al.* Clustered environments and randomized genes: a fundamental
1552 distinction between conventional and genetic epidemiology. *PLoS Med* **4**, e352,
1553 doi:10.1371/journal.pmed.0040352 (2007).
- 1554 24 Tyrrell, J. *et al.* Genetic Evidence for Causal Relationships Between Maternal Obesity-
1555 Related Traits and Birth Weight. *JAMA : the journal of the American Medical
1556 Association* **315**, 1129-1140, doi:10.1001/jama.2016.1975 (2016).
- 1557 25 Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization studies:
1558 subsample and 2-sample instrumental variable estimators. *American journal of
1559 epidemiology* **178**, 1177-1184, doi:10.1093/aje/kwt084 (2013).
- 1560 26 Walton, A. & Hammond, J. The maternal effects on growth and conformation in shire
1561 horse-shetland pony crosses. *Proceedings of the Royal Society of London. Series B -
1562 Biological Sciences* **125**, 311-335, doi:10.1098/rspb.1938.0029 (1938).
- 1563 27 Smith, D. W. *et al.* Shifting linear growth during infancy: illustration of genetic factors
1564 in growth from fetal life through infancy. *The Journal of pediatrics* **89**, 225-230
1565 (1976).
- 1566 28 Sorensen, T. *et al.* Comparison of associations of maternal peri-pregnancy and
1567 paternal anthropometrics with child anthropometrics from birth through age 7 y
1568 assessed in the Danish National Birth Cohort. *The American journal of clinical
1569 nutrition* **104**, 389-396, doi:10.3945/ajcn.115.129171 (2016).
- 1570 29 Hypponen, E., Power, C. & Smith, G. D. Parental growth at different life stages and
1571 offspring birthweight: an intergenerational cohort study. *Paediatr Perinat Epidemiol*
1572 **18**, 168-177, doi:10.1111/j.1365-3016.2004.00556.x (2004).
- 1573 30 Knight, B. *et al.* Evidence of genetic regulation of fetal longitudinal growth. *Early
1574 Hum Dev* **81**, 823-831, doi:10.1016/j.earlhumdev.2005.06.003 (2005).
- 1575 31 Nahum, G. G. & Stanislaw, H. Relationship of paternal factors to birth weight. *The
1576 Journal of reproductive medicine* **48**, 963-968 (2003).

1577 32 Griffiths, L. J., Dezateux, C. & Cole, T. J. Differential parental weight and height
1578 contributions to offspring birthweight and weight gain in infancy. *International*
1579 *journal of epidemiology* **36**, 104-107, doi:10.1093/ije/dyl210 (2007).

1580 33 Wood, A. R. *et al.* Defining the role of common variation in the genomic and
1581 biological architecture of adult human height. *Nat Genet* **46**, 1173-1186,
1582 doi:10.1038/ng.3097 (2014).

1583 34 Zhang, G. *et al.* Assessing the Causal Relationship of Maternal Height on Birth Size
1584 and Gestational Age at Birth: A Mendelian Randomization Analysis. *PLoS Med* **12**,
1585 e1001865, doi:10.1371/journal.pmed.1001865 (2015).

1586 35 Tyrrell, J. *et al.* Height, body mass index, and socioeconomic status: mendelian
1587 randomisation study in UK Biobank. *Bmj* **352**, i582, doi:10.1136/bmj.i582 (2016).

1588 36 Li, X., Redline, S., Zhang, X., Williams, S. & Zhu, X. Height associated variants
1589 demonstrate assortative mating in human populations. *Scientific reports* **7**, 15689,
1590 doi:10.1038/s41598-017-15864-x (2017).

1591 37 Pedersen, J. *Diabetes in pregnancy: blood sugar of newborn infants*, (1952).

1592 38 Metzger, B. E. *et al.* Hyperglycemia and adverse pregnancy outcomes. *The New*
1593 *England journal of medicine* **358**, 1991-2002, doi:10.1056/NEJMoa0707943 (2008).

1594 39 Crowther, C. A. *et al.* Effect of treatment of gestational diabetes mellitus on
1595 pregnancy outcomes. *The New England journal of medicine* **352**, 2477-2486,
1596 doi:10.1056/NEJMoa042973 (2005).

1597 40 Jarvelin, M. R. *et al.* Early life factors and blood pressure at age 31 years in the 1966
1598 northern Finland birth cohort. *Hypertension* **44**, 838-846,
1599 doi:10.1161/01.HYP.0000148304.33869.ee (2004).

1600 41 Tu, Y. K., West, R., Ellison, G. T. & Gilthorpe, M. S. Why evidence for the fetal origins
1601 of adult disease might be a statistical artifact: the "reversal paradox" for the relation
1602 between birth weight and blood pressure in later life. *American journal of*
1603 *epidemiology* **161**, 27-32, doi:10.1093/aje/kwi002 (2005).

1604 42 Huxley, R., Neil, A. & Collins, R. Unravelling the fetal origins hypothesis: is there really
1605 an inverse association between birthweight and subsequent blood pressure? *Lancet*
1606 **360**, 659-665, doi:10.1016/s0140-6736(02)09834-3 (2002).

1607 43 Yaghootkar, H. & Freathy, R. M. Genetic origins of low birth weight. *Current opinion*
1608 *in clinical nutrition and metabolic care* **15**, 258-264,
1609 doi:10.1097/MCO.0b013e328351f543 (2012).

1610 44 Lawlor, D. *et al.* Using Mendelian randomization to determine causal effects of
1611 maternal pregnancy (intrauterine) exposures on offspring outcomes: Sources of bias
1612 and methods for assessing them. *Wellcome open research* **2**, 11,
1613 doi:10.12688/wellcomeopenres.10567.1 (2017).

1614 45 Wang, T. *et al.* Low birthweight and risk of type 2 diabetes: a Mendelian
1615 randomisation study. *Diabetologia* **59**, 1920-1927, doi:10.1007/s00125-016-4019-z
1616 (2016).

1617 46 Freathy, R. M. Can genetic evidence help us to understand the fetal origins of type 2
1618 diabetes? *Diabetologia* **59**, 1850-1854, doi:10.1007/s00125-016-4057-6 (2016).

1619 47 Zanetti, D. *et al.* Birthweight, Type 2 Diabetes and Cardiovascular Disease:
1620 Addressing the Barker Hypothesis with Mendelian randomization. *bioRxiv*,
1621 doi:10.1101/208629 (2017).

1622 48 Zimmermann, E., Gamborg, M., Sorensen, T. I. & Baker, J. L. Sex Differences in the
1623 Association Between Birth Weight and Adult Type 2 Diabetes. *Diabetes* **64**, 4220-
1624 4225, doi:10.2337/db15-0494 (2015).

1625 49 Gamborg, M. *et al.* Birth weight and systolic blood pressure in adolescence and
1626 adulthood: meta-regression analysis of sex- and age-specific results from 20 Nordic
1627 studies. *American journal of epidemiology* **166**, 634-645, doi:10.1093/aje/kwm042
1628 (2007).

1629 50 Kong, A. *et al.* The nature of nurture: Effects of parental genotypes. *Science (New*
1630 *York, N.Y.)* **359**, 424-428, doi:10.1126/science.aan6877 (2018).

1631 51 Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants.
1632 *bioRxiv*, doi:10.1101/166298 (2017).

1633 52 Loh, P. R. *et al.* Efficient Bayesian mixed-model analysis increases association power
1634 in large cohorts. *Nat Genet* **47**, 284-290, doi:10.1038/ng.3190 (2015).

1635 53 Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74,
1636 doi:10.1038/nature15393 (2015).

1637 54 Magi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-
1638 analysis. *BMC bioinformatics* **11**, 288, doi:10.1186/1471-2105-11-288 (2010).

1639 55 Ioannidis, J. P., Patsopoulos, N. A. & Evangelou, E. Heterogeneity in meta-analyses of
1640 genome-wide association investigations. *PloS one* **2**, e841,
1641 doi:10.1371/journal.pone.0000841 (2007).

1642 56 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
1643 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295,
1644 doi:10.1038/ng.3211
1645 <http://www.nature.com/ng/journal/v47/n3/abs/ng.3211.html#supplementary-information>
1646 (2015).

1647 57 Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide
1648 complex trait analysis. *American journal of human genetics* **88**, 76-82,
1649 doi:10.1016/j.ajhg.2010.11.011 (2011).

1650 58 Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
1651 association studies using summary statistics. *PLoS Genet* **10**, e1004383,
1652 doi:10.1371/journal.pgen.1004383 (2014).

1653 59 Ihaka, R., Gentleman R. R: a language for data analysis and graphics. *Journal of*
1654 *Computational and Graphical Statistics* **5**, 299-314 (1996).

1655 60 Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide
1656 association studies. *Nat Genet* **48**, 245-252, doi:10.1038/ng.3506 (2016).

1657 61 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
1658 genomewide association scans. *Bioinformatics (Oxford, England)* **26**, 2190-2191,
1659 doi:10.1093/bioinformatics/btq340 (2010).

1660 62 Mardia, K. V. *Multivariate analysis / K.V. Mardia, J.T. Kent, J.M. Bibby.* (Academic
1661 Press, 1979).

1662 63 Segre, A. V., Groop, L., Mootha, V. K., Daly, M. J. & Altshuler, D. Common inherited
1663 variation in mitochondrial genes is not enriched for associations with type 2 diabetes
1664 or related glycemic traits. *PLoS Genet* **6**, doi:10.1371/journal.pgen.1001058 (2010).

1665 64 Frayling, T. M. *et al.* A Common Allele in FGF21 Associated with Sugar Intake Is
1666 Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood
1667 Pressure. *Cell reports* **23**, 327-336, doi:10.1016/j.celrep.2018.03.070 (2018).

1668 65 Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score
1669 regression that maximizes the potential of summary level GWAS data for SNP
1670 heritability and genetic correlation analysis. *Bioinformatics (Oxford, England)*,
1671 doi:10.1093/bioinformatics/btw613 (2016).
1672 66 Prokopenko, I. *et al.* A central role for GRB10 in regulation of islet function in man.
1673 *PLoS Genet* **10**, e1004235, doi:10.1371/journal.pgen.1004235 (2014).
1674 67 Burgess, S., Scott, R. A., Timpson, N. J., Davey Smith, G. & Thompson, S. G. Using
1675 published data in Mendelian randomization: a blueprint for efficient identification of
1676 causal risk factors. *European journal of epidemiology* **30**, 543-552,
1677 doi:10.1007/s10654-015-0011-z (2015).
1678 68 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
1679 instruments: effect estimation and bias detection through Egger regression.
1680 *International journal of epidemiology* **44**, 512-525, doi:10.1093/ije/dyv080 (2015).
1681 69 Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
1682 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
1683 Estimator. *Genetic epidemiology* **40**, 304-314, doi:10.1002/gepi.21965 (2016).
1684 70 Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for
1685 disease and population genetic studies. *Nature methods* **10**, 5-6,
1686 doi:10.1038/nmeth.2307 (2013).
1687 71 Manichaikul, A. *et al.* Robust relationship inference in genome-wide association
1688 studies. *Bioinformatics (Oxford, England)* **26**, 2867-2873,
1689 doi:10.1093/bioinformatics/btq559 (2010).
1690
1691
1692
1693

Acknowledgements:

Full acknowledgements and supporting grant details can be found in the Supplementary material.

Author contributions:

Central analysis and writing team: N.M.W., R.N.B., M.H., F.R.D., K.K.O., M.I.M., J.R.P., D.M.E., R.M.F.

Statistical analysis: N.M.W., R.N.B., M.H., F.R.D., Ø.H., C.Laurin, J.B., S.P., K.H., B.F., A.R.W., A.Mahajan, J.T., N.R.R., N.W.R., Z.Q., G-H.Ø.M., M.Vaudel, M.N., T.M.S., M.H.Z., J.P.B., N.G., M.N.K., R.L-G., F.G., T.S.A., L.P., R.R., V.H., J-J.H., L-P.L., A.C., S.M., D.L.C., Y.W., E.T., C.A.W., C.T.H., N.V-T., P.K.J., J.N.P., I.N., R.M., N.P., E.M.v.L., R.J., V.L., R.C.R., A.E., S.J.B., W.A., J.A.M., K.L.L., C.A., G.Z., L.J.M., J.Heikkinen, A.H.v.K., K.J.G., N.R.v.Z., C.M-G., Z.K., S.D., H.M., E.V.R.A., M.Murcia, S.B-G., D.M.H., J.M.Mercader, K.E.S., P.A.L., S.E.M., B.M.S., J-F.C., K.Panoutsopoulou, F.S., D.T., I.P., M.A.T., H.Y., K.S.R., S.E.J., P-R.L., A.Murray, M.N.W., E.Z., G.V.D., Y-Y.T., M.G.H., K.L.M., J.F.F., D.M.S., N.J.T., A.P.M., D.A.L., J.R.P., D.M.E., R.M.F.

Genotyping: F.R.D., Ø.H., T.M.S., M.H.Z., N.G., R.L-G., L.P., J-J.H., L-P.L., J.W.H., X.E., L.M., L.B., C.S.M., C.Langenberg, J'a.L., R.A.S., J.H.Z., G.H., S.M.R., A.J.B., J.F-T., C.M-G., H.G.d.H., F.R.R., Z.K., P.M-V., H.M., E.V.R.A., M.Bustamante, M.A., P.K., M.Stumvoll, T.A.L., C.M.v.D., A.K., E.Z., S-M.S., G.W.M., H.C., J.F.W., T.G.V., C.E.P., E.E.W., T.D.S., T.L., P.V., H.B., K.B., J.C.M., F.R., J.F.F., T.H., O.P., A.G.U., M-R.J., W.L.L.Jr, G.D.S., N.J.T., N.J.W., H.H., S.F.G., T.M.F., D.A.L., P.R.N., K.K.O., M.I.M., J.R.P., D.M.E., R.M.F.

Sample collection and phenotyping: F.R.D., B.F., C.J.M., J.C., J.P.B., M.N.K., R.L-G., F.G., R.R., I.N., H.M.I., J.W.H., L.S-M., C.R., B.H., M.Kogevinas, L.C., M-F.H., C.S.M., F.D.M., C.Langenberg, J'a.L., R.A.S., J.H.Z., S.M.R., C.M-G., H.G.d.H., Z.K., P.M-V., S.D., G.W., M.M-N., M.Standl, C.E.F., C.T., C.E.v.B., M.Bustamante, D.M.H., A.L., B.A.K., M.Bartels, J.S., R.K.V., S.M.W., B.L.C., A.T., K.F.M., A-M.E., T.A.L., A.K., H.N., K.Pahkala, O.T.R., B.J., G.V.D., S-M.S., G.W.M., J.F.W., T.G.V., M.Vrijheid, J-C.H., L.J.B., C.E.P., L.S.A., J.B.B., J.G.E., E.E.W., A.T.H., T.D.S., M.Kähönen, J.S.V., T.L., P.V., H.B., K.B., M.Melbye, E.A.N., D.O.M-K., J.F.F., V.W.J., C.Pisinger, A.A.V., M-R.J., C.Power, E.H., W.L.L.Jr, G.D.S., N.J.W., H.H., S.F.G., D.A.L., K.K.O., M.I.M., J.R.P.

Study Design and Principal Investigators: J.P.B., I.N., H.M.I., L.S-M., X.E., B.H., J.M.Murabito, M.Kogevinas, L.C., M-F.H., F.D.M., M.A., A.T., M.Stumvoll, K.F.M., A-M.E., T.A.L., C.M.v.D., W.K., A.K., H.N., K.Pahkala, O.T.R., B.J., G.V.D., Y-Y.T., S-M.S., G.W.M., H.C., J.F.W., T.G.V., M.Vrijheid, E.J.d.G., H.N.K., J-C.H., L.J.B., C.E.P., J.Heinrich, L.S.A., J.B.B., K.L.M., J.G.E., E.E.W., A.T.H., T.D.S., M.Kähönen, J.S.V., T.L., D.I.B., S.S., P.V., H.B., K.B., J.C.M., M.Melbye, E.A.N., D.O.M-K., F.R., J.F.F., V.W.J., T.H., C.Pisinger, A.A.V., O.P., A.G.U., M-R.J., C.Power, E.H., W.L.L.Jr, N.J.T., A.P.M., N.J.W., H.H., S.F.G., T.M.F., D.A.L., P.R.N., S.J., K.K.O., M.I.M., J.R.P., R.M.F.

Competing interests statement

A.A.V. is an employee of AstraZeneca. D.A.L. has received support from Medtronic LTD and Roche Diagnostics for biomarker research that is not related to the study presented in this paper. M.I.M. serves on advisory panels for Pfizer, NovoNordisk, Zoe Global; has received honoraria from Merck, Pfizer, NovoNordisk and Eli Lilly; has stock options in Zoe Global; has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, Takeda.